Index to Volume 25

Author Index

- A -

Abbruscato TJ: see Rudd KM, et al, 1592
Abughosh SM: see Kogut SJ, et al, 1729
ACCP, Gray T, Bertch K, Galt K, Gonyeau M, Karpiuk E, Oyen L, Sudekum MJ, Vermeulen LC: Guidelines for Therapeutic Interchange—2004, 1666
ACCP, Linnebur SA, O'Connell MB, Wessell AM, McCord AD, Kennedy DH, DeMaagd G, Dent LA, Splinter MY, Biery Jr JC, Chang F, Jackson RC, Miller SL, Sterling T: Pharmacy Practice, Research, Education, and Advocacy for Older Adults, 1396
ACCP: 2005 Annual Meeting Abstracts and Index of Authors, 1431
ACCP: 2005 Spring Practice Forum Abstracts and Index of Authors, 451
Adams CD, Szumita PM, Baroletti SA, Lilly CM: Azacitidine-Induced Interstitial and Alveolar Fibrosis in a Patient with Myelodysplastic Syndrome, 765
Akins RL, Haase KK: Gram-Positive Resistance: Pathogens, Implications, and Treatment Options: Insights from the Society of Infectious Diseases Pharmacists, 1001
Alaniz C: see Butler SO, et al, 963
Aldag JC: see Graumlich JF, et al, 1296
Aldrich JL: see Brady KA, et al, 10
Alexander EW, Duane BB: Bispectral Index Monitoring in the Intensive Care Unit, 1681
Allen-Ramey FC, Anstatt DT, Sajjan SG, Markson LE: Asthma-Related Health Care Resource Use Among Patients Starting Fluticasone or Montelukast Therapy, 1752
Alvarez J-C: see Dulac O, et al, 35
Amaya CJ: see Busti AJ, et al, 1566
Ambegaonkar AJ: see Lewis II JS, et al, 839
Amsden JR, Warmack S, Gubbins PO: Tick-Borne Bacterial, Rickettsial, Spirochetal, and Protozoal Infectious Diseases in the United States: A Comprehensive Review, 191
Amsden JR: see Slain D, et al, 165
Anaya JP, Sias JJ: The Use of Interleukin-2 in Human Immunodeficiency Virus Infection, 86
Anderson Jr HG: see McCall KL, et al, 67
Andes DR: see Bhavnani SM, et al, 717
Andrus MR: see Roth MT, et al, 279
Angulo F: see Perez-Verdia A, et al, 1271
Ansell J: see Wittkowsky AK, et al, 265
Anstatt DT: see Allen-Ramey FC, et al, 1752
Antoniou T, Gough KA: Early-Onset Pentamidine-Associated Second-Degree Heart Block and Sinus Bradycardia: Case Report and Review of the Literature, 899
Argo TR: see Kukoyi O, et al, 435
Arnold LM, Nissen LR, Ng TMH: Moxifloxacin and Warfarin: Additional Evidence for a Clinically Relevant Interaction, 904
Arnsten JH: see Krantz MJ, et al, 1523
Arpaci F: see Uner A, et al, 1011
Arpino PA, Demirjian Z, Van Cott EM: Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin, 157
Arunakul VL: see Craycraft ME, et al, 308
Aubert RE: see Teagarden JR, et al, 1629
Aucoin RG, Buck ML, Dupuis LL, Dominguez KD, Smith KP: Pediatric Pharmacotherapeutic Education: Current Status and Recommendations to Fill the Growing Need, 1277
Avelino RR: see Graumlich JF, et al, 1296
Ayani I: see Gómez-Criado MS, et al, 1660

- B -

Bailey EM: see Cahill Jr JB, et al, 116
Bailie GR, Massry SG: Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease: An Overview, 1687
Bailie GR, Uhlig K, Levey AS: Clinical Practice Guidelines in Nephrology: Evaluation, Classification, and Stratification of Chronic Kidney Disease, 491
Ballard EE: see Skrepnek GH, et al, 325
Barner JC: see Sanchez RJ, et al, 909
Barnett MJ, Milavetz G, Kaboli PJ: β-Blocker Therapy in Veterans with Asthma or Chronic Obstructive Pulmonary Disease, 1550
Baroletti SA: see Adams CD, et al, 765
Baskin RC: see Motl SE, et al, 1151
Bastani B: see Malik A, et al, 769
Batts D: see Curtis JM, et al, 876
Bauer L: Creatinine Clearance versus Glomerular Filtration Rate for the Use of Renal Drug Dosing in Patients with Kidney Dysfunction, 1286
Benavides S, Striet J, Germak J, Nahata MC: Efficacy and Safety of Hypoglycemic Drugs in Children with Type 2 Diabetes Mellitus, 803
Berges AA: see Stoner SC, et al, 1651
Bernardo M: see Gómez-Criado MS, et al, 1660
Bertch K: see ACCP, et al, 1666
Bestul MB, VandenBussche HL: Antibiotic Lock Technique: Review of the Literature, 211
Bettinger T: see Sanchez RJ, et al, 909
Bhargava VO: see Shi J, et al, 42
Bhattacharya S: see Covelli H, et al, 1708
Bhavnani SM, Andes DR: Gemifloxacin for the Treatment of Respiratory Tract Infections: In Vitro Susceptibility, Pharmacokinetics and Pharmacodynamics, Clinical Efficacy, and Safety, 717
Bickford CL, Spencer AP: Biliary Sludge and

Hyperbilirubinemia Associated with Ceftriaxone in an Adult: Case Report and Review of the Literature, 1389
Bickley S: see Malani PN, et al, 690
Biery Jr JC: see ACCP, et al, 1396
Billett HH: see Shprecher AR, et al, 817
Binkley K: see Knowles SR, et al, 1258
Blackburn DF, Dobson RT, Blackburn JL, Wilson TW: Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy, 1035
Blackburn JL: see Blackburn DF, et al, 1035
Blumer J: Introduction to Scientific Basis for Tissue-Directed Antimicrobial Therapy supplement, 101S
Boerth JM, Caley CF, Goethe JW: Interpreting Serum Risperidone Concentrations, 299
Bond CA: see Rudd KM, et al, 1592
Bookwalter T, Gitlin M: Gabapentin-Induced Neurologic Toxicities, 1817
Bosinski TJ: see Kolade VO, et al, 1017
Bosso JA: The Antimicrobial Armamentarium: Evaluating Current and Future Treatment Options, 55S
Boston RC: see Brady KA, et al, 10
Boucher HW: see Lewis II JS, et al, 839
Boullata JI: see Santos CA, et al, 1789
Bowles SK: see Kephart G, et al, 1248
Bradley JS: Pharmacodynamics and the Prediction of Efficacy in Short-Course Antibiotic Therapy: Pediatric Studies to Validate the Model, 159S
Brady KA, Boston RC, Aldrich JL, MacGregor RR: Stavudine Entry into Cerebrospinal Fluid After Single and Multiple Doses in Patients Infected with Human Immunodeficiency Virus, 10
Bratzler DW: see Chang NN, et al, 59
Bridy-Pappas AE, Margolis MB, Center KJ, Isaacman DJ: Streptococcus pneumoniae: Description of the Pathogen, Disease Epidemiology, Treatment, and Prevention, 1193
Britton ML: see Hughes DV, et al, 1602
Brooks JM: see Chrischilles EA, et al, 668
Brophy GM: see Erstad BL, et al, 585
Brouse SD, Phillips SM: Amiodarone Use in Patients with Documented Allergy to Iodine-Containing Compounds, 429
Brucculeri M, Kaplan J, Lande L: Reversal of Citalopram-Induced Junctional Bradycardia with Intravenous Sodium Bicarbonate, 119
Btaiche IF: see Butler SO, et al, 963
Buchan DA: see Phillips EM, et al, 1341
Buck ML, Wooldridge P, Ksenich RA: Comparison of Methods for Intravenous Infusion of Fat Emulsion During Extracorporeal Membrane Oxygenation, 1536
Buck ML: see Aucoin RG, et al, 1277
Bultemeier NC: see Hartung DM, et al, 1329
Burgess DS: see Frei CR, et al, 1161
Burkiewicz JS: Effect of Access to Anticoagulation Management Services on Warfarin Use in Patients with Atrial Fibrillation, 1062
Burns TL, Mooss AN, Hilleman DE: Antiplatelet Drug Resistance: Not Ready for Prime Time, 1621
Bussey HI: see Reese AM, et al, 1746
Bussey HI: see Rychlik PG, et al, 1112
Busti AJ, Hooper JS, Amaya CJ, Kazi S: Effects of Perioperative Antiinflammatory and Immunomodulating Therapy on Surgical Wound Healing, 1566
Butler SO, Btaiche IF, Alaniz C: Relationship Between Hyperglycemia and Infection in Critically Ill Patients, 963
Byrnes CA, Shepler BM: Cinacalcet: A New Treatment for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis, 709

- C -

Cahill GM: see Mayo JL, et al, 520
Cahill Jr JB, Bailey EM, Chien S, Johnson GM: Levofloxacin Secretion in Breast Milk: A Case Report, 116
Caley CF: see Boerth JM, et al, 299
Camamo JM, McCoy RH, Erstad BL: Retrospective Evaluation of Inhaled Prostaglandins in Patients with Acute Respiratory Distress Syndrome, 184
Capling R: see Malik A, et al, 769
Carnahan RM, Kutscher EC, Obritsch MD, Rasmussen LD: Acute Ethanol Intoxication After Consumption of Hairspray, 1646
Carnahan RM: see Kukoyi O, et al, 435
Carroll NM: see Raebel MA, et al, 1055
Carroll NM: see Shanahan RL, et al, 345
Cartier LL: see Sawchuk RJ, et al, 140S
Cassino C: see Covelli H, et al, 1708
Castelli EE, Culley CM, Fink MP: Challenge and Rechallenge: Drotrecogin alfa (activated)–Induced Prolongation of Activated Partial Thromboplastin Time in a Patient with Severe Sepsis, 1147
Center KJ: see Bridy-Pappas AE, et al, 1193
Chamilos G: see Lionakis MS, et al, 1174
Chan HO: see Wong S-F, et al, 372
Chang C-M, Liu P-YY, Yang Y-HK, Yang Y-C, Wu C-F, Lu F-H: Use of the Beers Criteria to Predict Adverse Drug Reactions Among First-Visit Elderly Outpatients, 831
Chang F: see ACCP et al, 1396
Chang NN, Murray CK, Houck PM, Bratzler DW, Greenway C, Guglielmo BJ: Blood Culture and Susceptibility Results and Allergy History Do Not Influence Fluoroquinolone Use in the Treatment of Community-Acquired Pneumonia, 59
Chant C, Wilson G, Friedrich JO: Validation of an Insulin Infusion Nomogram for Intensive Glucose Control in Critically Ill Patients, 352
Chauhan BM: see van Heeswijk RPG, et al, 1725
Chavin KD: see Markowitz JS, et al, 1337
Chawla S: see Rivkin AM, et al, 862
Chen C-C: see Tsai J-H, et al, 1156
Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G: Meta-Analysis of Natural Therapies for Hyperlipidemia: Plant Sterols and Stanols versus Policosanol, 171

Chen J-Y: see Fang W, et al, 1266
Chen K-H: see Wu F-LL, et al, 646
Chen RR-L: see Wu F-LL, et al, 646
Cheng-Lai A: see Shprecher AR, et al, 817
Chen-Hardee SS: see Chrischilles EA, et al, 668
Cheung BWY: see Sawchuk RJ, et al, 140S
Chien S: see Cahill Jr JB, et al, 116
Chin H: see Dornbrook-Lavender KA, et al, 325
Chong PH, Varner D: Cost-Efficacy Analysis of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Based on Results of the STELLAR Trial: Clinical Implications for Therapeutic Selection, 270
Chonlahan J: see Havrda DE, et al, 303
Chrischilles EA, Klepser DG, Brooks JM, Voelker MD, Chen-Hardee SS, Scott SD, Link BK, Delgado DJ: Effect of Clinical Characteristics on Neutropenia-Related Inpatient Costs Among Newly Diagnosed, Non-Hodgkin's Lymphoma Cases During First-Course Chemotherapy, 668
Chumney ECG: see Ragucci KR, et al, 1809
Ciccarelli L: see Derosa G, et al, 637
Cicero AFG: see Derosa G, et al, 637
Cios D: see Min B, et al, 1719
Clark BM, Schofield RS: Dilated Cardiomyopathy and Acute Liver Injury Associated with Combined Use of Ephedra, γ-Hydroxybutyrate, and Anabolic Steroids, 756
Clifford TM, Pajoumand M, Johnston TD: Celecoxib-Induced Nephrotoxicity in a Renal Transplant Recipient, 773
Cluxton RJ: see Guo JJ, et al, 1044
Cohard-Radice M: see Shetzline MA, et al, 1684
Cohen HW: see Shprecher AR, et al, 817
Cole PD: see Mantadakis E, et al, 748
Coleman CI, Gillespie EL, White CM: Probable Topical Permethrin-Induced Neck Dystonia, 448
Coleman CI: see Perkerson KA, et al, 320
Collins CD: see Eschenauer G, et al, 630
Combe C, Tredree RL, Schellekens H: Biosimilar Epoetins: An Analysis Based on Recently Implemented European Medicines Evaluation Agency Guidelines on Comparability of Biopharmaceutical Proteins, 954
Connolly LA: see Sakai EM, et al, 1773
Conoscenti C: see Covelli H, et al, 1708
Cooke CA: see Kephart G, et al, 1248
Cooper CL: see van Heeswijk RPG, et al, 1725
Cooper SL: see Straka RJ, et al, 360
Copeland LA: see O'Neill JL, et al, 1560
Coronel SM: see Krantz MJ, et al, 1826
Couch PL: see Rosborough TK, et al, 823
Courtney P: see Teagarden JR, et al, 1629
Covelli H, Bhattacharya S, Cassino C, Conoscenti C, Kesten S: Absence of Electrocardiographic Findings and Improved Function with Once-Daily Tiotropium in Patients with Chronic Obstructive Pulmonary Disease, 1708
Craycraft ME, Arunakul VL, Humeniuk JM: Probable Vancomycin-Associated Toxic Epidermal Necrolysis, 308
Crismon ML: see Patel NC, et al, 1242
Crismon ML: see Sanchez RJ, et al, 909
Cross LB: see Self TH, et al, 526
Csako G: see Chen JT, et al, 171
Culhane NS, Lettieri SL, Skae JR: Rosuvastatin for the Treatment of Hypercholesterolemia, 990
Culley CM: see Castelli EE, et al, 1147
Curtis JM, Sternhagen V, Batts D: Acute Renal Failure After Placement of Tobramycin-Impregnated Bone Cement in an Infected Total Knee Arthroplasty, 876

- D -

Dagenais NJ, Jamali F: Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions, 1213
Daniel KP: see Pizzimenti JJ, et al, 1141
Darkow T, Fontes CL, Williamson TE: Costs Associated with the Management of Overactive Bladder and Related Comorbidities, 511
Davis DA, Fugate SE: Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy, 442
Davis ME: see Van Brunt DL, et al, 1541
Day DL: see Lewis II JS, et al, 839
de Florez T: see Gómez-Criado MS, et al, 1660
DeEugenio DL, Ruggiero II NJ, Thomson LJ, Menajovsky LB, Herman JH: Early-Onset Heparin-Induced Thrombocytopenia After a 165-Day Heparin-Free Interval: Case Report and Review of the Literature, 615
DeHart RM: see Zillich AJ, et al, 123
Delgado DJ: see Chrischilles EA, et al, 668
DeMaagd G: see ACCP, et al, 1396
Demirjian Z: see Arpino PA, et al, 157
Dent LA: see ACCP, et al, 1396
Denu-Ciocca CJ: see Dornbrook-Lavender KA, et al, 325
DePestel DD: see Malani PN, et al, 690
Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AFG: Antithrombotic Effects of Rosiglitazone-Metformin versus Glimepiride-Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome, 637
DeVane CL: see Markowitz JS, et al, 1337
Devlin JW, Lau AK, Tanios MA: Propofol-Associated Hypertriglyceridemia and Pancreatitis in the Intensive Care Unit: An Analysis of Frequency and Risk Factors, 1348
DiBaise JK: Tegaserod-Associated Ischemic Colitis, 620
DiPiro JT: see Rychly DJ, et al, 1181
Dobson RT: see Blackburn DF, et al, 1035
Dominguez KD: see Aucoin RG, et al, 1277
Donovan JL: see Markowitz JS, et al, 1337
Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA: Effects of Atorvastatin on Low-Density Lipoprotein Cholesterol Phenotype and C-Reactive Protein Levels in Patients Undergoing Long-Term Dialysis, 335

Draugalis JR: see Joish VN, et al, 676
Drewe J: see Egger SS, et al, 881
Drusano GL: Infection Site Concentrations: Their Therapeutic Importance and the Macrolide and Macrolide-Like Class of Antibiotics, 150S
Duane BB: see Alexander EW, et al, 1681
Duggan JM, Sahloff EG, Moudgal VV: Use of Highly Active Antiretroviral Therapy in Patients with Renal Insufficiency, 698
Dulac O, Alvarez J-C: Bioequivalence of a New Sustained-Release Formulation of Sodium Valproate, Valproate Modified-Release Granules, Compared with Existing Sustained-Release Formulations After Once- or Twice-Daily Administration, 35
Dumo P: see Zillich AJ, et al, 123
Dupuis LL: see Aucoin RG, et al, 1277

- E -

Egger SS, Sawatzki MG, Drewe J, Krähenbühl S: Life-Threatening Hemorrhage After Dalteparin Therapy in a Patient with Impaired Renal Function, 881
Elhabyan A: see Miller MG, et al, 847
El-Maouche D: see Kogut SJ, et al, 1729
Epstein BJ, Gums JG: Can the Renin-Angiotensin System Protect Against Stroke? A Focus on Angiotensin II Receptor Blockers, 531
Epstein RS: see Teagarden JR, et al, 1629
Ergul A: see Fagan SC, et al, 387
Ericsson CD: see Mohr JF, et al, 426
Erstad BL, Martin SJ, Brophy GM, Haas CE, Jacobi J, Welage LS, Thomas MC: Key Articles and Guidelines Relative to Intensive Care Unit Pharmacology—2004, 585
Erstad BL: see Camamo JM, et al, 184
Eschenauer G, Collins CD, Regal RE: Azithromycin-Warfarin Interaction: Are We Fishing with a Red Herring?, 630
Eurich DT, Simpson SH, Majumdar SR, Johnson JA: Secondary Failure Rates Associated with Metformin and Sulfonylurea Therapy for Type 2 Diabetes Mellitus, 810
Evans CG: see Formea CM, et al, 1021
Evans M, Lewis GM: Increase in International Normalized Ratio After Smoking Cessation in a Patient Receiving Warfarin, 1656
Evans ME: see Grim SA, et al, 253

- F -

Fagan SC, Hess DC, Machado LS, Hohnadel EJ, Pollock DM, Ergul A: Tactics for Vascular Protection After Acute Ischemic Stroke, 387
Fang W, Chen J-Y, Fang Y, Huang J-L: Epinephrine Overdose–Associated Hypokalemia and Rhabdomyolysis in a Newborn, 1266
Fang Y: see Fang W, et al, 1266
Farnett LE: see Reese AM, et al, 1746
Fermo JD: see Ragucci KR, et al, 1809
Ferrari I: see Derosa G, et al, 637
Field KM: Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors on High-Sensitivity C-Reactive Protein Levels, 1365
Fike DS: see MacLaughling EJ, et al, 379
Finch CK: see Self TH, et al, 526
Fink MP: see Castelli EE, et al, 1147
Finn WF: see Joy MS, et al, 779
Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR: Current Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction, 503
Fish DN: see Kiser TH, et al, 1736
Fish DN: see Obritsch MD, et al, 1353
Fisher MA: see Slain D, et al, 165
Flanagan PS: see O'Neill JL, et al, 1560
Fontes CL: see Darkow T, et al, 511
Formea CM, Evans CG, Karlix JL: Altered Cytochrome P450 Metabolism of Calcineurin Inhibitors: Case Report and Review of the Literature, 1021
Foster BC: see van Heeswijk RPG, et al, 1725
Franks AR: see Self TH, et al, 526
Fraser GL, Riker RR: Bispectral Index Monitoring in the Intensive Care Unit Provides More Signal Than Noise, 19S
Fraser GL: see Riker RR, et al, 8S
Frei CR, Burgess DS: Pharmacodynamic Analysis of Ceftriaxone, Gatifloxacin, and Levofloxacin Against Streptococcus pneumoniae with the Use of Monte Carlo Simulation, 1161
Frei-Lahr DA: see Niedermeier DM, et al, 1134
Friedrich JO: see Chant C, et al, 352
Fugate SE: see Davis DA, et al, 442
Fugate SE: see Stout DL, et al, 244
Fujino T: see Kusaba T, et al, 52

- G -

Gaddamanugu M: see Graumlich JF, et al, 1296
Gaddi AV: see Derosa G, et al, 637
Galt K: see ACCP, et al, 1666
Gandía R: see Gómez-Criado MS, et al, 1660
Garcia JA: see Krantz MJ, et al, 611
Germak J: see Benavides S, et al, 803
Ghelfi M: see Derosa G, et al, 637
Giagoudakis G, Markantonis SL: Relationships Between the Concentrations of Prostaglandins and the Nonsteroidal Antiinflammatory Drugs Indomethacin, Diclofenac, and Ibuprofen, 18
Gillam DM: see Turner RC, et al, 626
Gillespie EL: see Coleman CI, et al, 448
Gillespie EL: see Perkerson KA, et al, 320
Gilmartin C: see Zillich AJ, et al, 123
Gitlin M: see Bookwalter T, et al, 1817
Gleason PP, Williams C, Hrdy S, Hartwig SC, Lassen D: Medical and Pharmacy Expenditures After Implementation of a Cyclooxygenase-2 Inhibitor Prior Authorization Program, 924
Goethe JW: see Boerth JM, et al, 299
Goldberg ME: see Larijani GE, et al, 1168
Goldman M: see Kays MB, et al, 1530
Goldman M: see Overholser BR, et al, 1310
Gómez-Criado MS, Bernardo M, de Florez T, Gutiérrez JR, Gandía R, Ayani I: Ziprasidone Overdose: Cases

Recorded in the Database of Pfizer-Spain and Literature Review, 1660
Gonyeau M: see ACCP, et al, 1666
Gonyeau MJ: Statins and Osteoporosis: A Clinical Review, 228
Gonzalez III LS: Study to Evaluate the Analgesic and Hemodynamic Effects of a Single Dose of Morphine—An Alternative Viewpoint, 1288
Gören JL: see Kirwin JL, et al, 396
Gough KA: see Antoniou T, et al, 899
Gourevitch MN: see Krantz MJ, et al, 1523
Grabe DW: see Zillich AJ, et al, 123
Gratz I: see Larijani GE, et al, 1168
Graumlich JF, Habis SH, Avelino RR, Salverson SM, Gaddamanugu M, Jamma K, Aldag JC: Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study, 1296
Gray T: see ACCP, et al, 1666
Greenblatt D: Treatment of Postmenopausal Osteoporosis, 574
Greenway C: see Chang NN, et al, 59
Grim SA, Rapp RP, Martin CA, Evans ME: Trimethoprim-Sulfamethoxazole as a Viable Treatment Option for Infections Caused by Methicillin-Resistant Staphylococcus aureus, 253
Gubbins PO: see Amsden JR, et al, 191
Guglielmo BJ: see Chang NN, et al, 59
Gums JG: see Epstein BJ, et al, 531
Guo JJ, Jang R, Louder A, Cluxton RJ: Acute Pancreatitis Associated with Different Combination Therapies in Patients Infected with Human Immunodeficiency Virus, 1044
Gutiérrez JR: see Gómez-Criado MS, et al, 1660

- H -

Haas CE: see Erstad BL, et al, 585
Haase KK: see Akins RL, et al, 1001
Habis SH: see Graumlich JF, et al, 1296
Hachey DM: see Zillich AJ, et al, 123
Hall AC: see Mohr JF, et al, 426
Hall PD: see Niedermeier DM, et al, 1134
Hallisey Jr RK: see John TE, et al, 1383
Handler SM: see Zerumsky K, et al, 797
Hardwicke FL: see Perez-Verdia A, et al, 1271
Harrison D: see Mullins CD, et al, 660
Hartung DM, Touchette DR, Bultemeier NC, Haxby DG: Risk of Hospitalization for Heart Failure Associated with Thiazolidinedione Therapy: A Medicaid Claims–Based Case-Control Study, 1329
Hartwig SC: see Gleason PP, et al, 924
Harvey III RD: Introduction to Immunoglobulin Intravenous Therapy: The Process, the Product, the Patient, and the Pocketbook supplement, 71S
Harvey III RD: The Patient: Emerging Clinical Applications of Intravenous Immunoglobulin, 85S
Hatta S: see Kusaba T, et al, 52
Havrda DE, Mai T, Chonlahan J: Enhanced Antithrombotic Effect of Warfarin Associated with Low-Dose Alcohol Consumption, 303
Haxby DG: see Hartung DM, et al, 1329
Henry KS: see Rychlik PG, et al, 1112
Herman JH: see DeEugenio DL, et al, 615
Herrington JD: see Jaskiewicz AD, et al, 1820
Hess DC: see Fagan SC, et al, 387
Hiatt WR: see Krantz MJ, et al, 1826
Hilaire M: see Self TH, et al, 526
Hilleman DE: see Burns TL, et al, 1621
Hobbs GR: see Slain D, et al, 165
Hogan SL: see Dornbrook-Lavender KA, et al, 325
Hogan SL: see Joy MS, et al, 779
Hogikyan ND: see Shehab N, et al, 977
Hohnadel EJ: see Fagan SC, et al, 387
Holdford DA: see Orensky IA, et al, 1801
Hooper JS: see Busti AJ, et al, 1566
Horowitz S: see Kuti JL, et al, 935
Houck PM: see Chang NN, et al, 59
Hrdy S: see Gleason PP, et al, 924
Hu R-H: see Wu F-LL, et al, 646
Huang J-D: see Wu F-LL, et al, 646
Huang J-L: see Fang W, et al, 1266
Hudson JQ: see Zillich AJ, et al, 123
Hughes DB, Britton ML: Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers for Prevention and Treatment of Nephropathy Associated with Type 2 Diabetes Mellitus, 1602
Humeniuk JM: see Craycraft ME, et al, 308
Humphries KH: see Shalansky SJ, et al, 1095

- I, J -

Imai G: see Kusaba T, et al, 52
Inciardi JF, Leeds AL: Assessing the Utility of a Community Pharmacy Refill Record as a Measure of Adherence and Viral Load Response in Patients Infected with Human Immunodeficiency Virus, 790
Isaacman DJ: see Bridy-Pappas AE, et al, 1193
Isakow W: see Micek ST, et al, 26
Ismali A: see Min B, et al, 654
Ismali A: see Perkerson KA, et al, 320
Itkin YM, Trujillo TC: Intravenous Immunoglobulin–Associated Acute Renal Failure: Case Series and Literature Review, 886
Jackson RC: see ACCP, et al, 1396
Jacobi J: Sedation Guidelines: Has the Road Map Brought Us to the Destination?, 1S
Jacobi J: see Erstad BL, et al, 585
Jacobs RF: see Muldrew KM, et al, 893
Jamali F: see Dagenais NJ, et al, 1213
Jamma K: see Graumlich JF, et al, 1296
Jang R: see Guo JJ, et al, 1044
Jarvinen JR: see Phillips DP, et al, 1
Jaskiewicz AD, Herrington JD, Wong L: Tumor Lysis Syndrome After Bortezomib Therapy for Plasma Cell Leukemia, 1820
Jennings DL, Kalus JS, O'Dell KM: Aldosterone Receptor Antagonism in Heart Failure, 1126
Ji P: see Sawchuk RJ, et al, 140S
Jick H: see Fischer LM, et al, 503
Joelsson B: see Shetzline MA, et al, 1684

John TE, Hallisey Jr RK: Argatroban and Lepirudin Requirements in a 6-Year-Old Patient with Heparin-Induced Thrombocytopenia, 1383
Johnson CE: see Prescott Jr WA, et al, 555
Johnson GM: see Cahill Jr JB, et al, 116
Johnson JA: see Eurich DT, et al, 810
Johnson JA: see Yamada C, et al, 110
Johnson MD: see Pope SD, et al, 1761
Johnsrud MT: see Patel NC, et al, 1242
Johnston JA: see Van Brunt DL, et al, 1541
Johnston TD: see Clifford TM, et al, 773
Joish VN, Malone DC, Wendel C, Draugalis JR, Mohler MJ: Development and Validation of a Diabetes Mellitus Severity Index: A Risk-Adjustment Tool for Predicting Health Care Resource Use and Costs, 676
Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF: Calcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P-glycoprotein, 779
Joy MS: see Dornbrook-Lavender KA, et al, 325
Joy MS: see Zillich AJ, et al, 123
Jung R: see Kiser TH, et al, 1736
Jung R: see Obritsch MD, et al, 1353

- K -

Kaboli PJ: see Barnett MJ, et al, 1550
Kalus JS: see Jennings DL, et al, 1126
Kamen BA: see Mantadakis E, et al, 748
Kammer RT: Lone Atrial Fibrillation Associated with Creatine Monohydrate Supplementation, 762
Kaplan J: see Brucculeri M, et al, 119
Kardas M: see Perkerson KA, et al, 320
Kardas MJ: see Min B, et al, 654
Karlix JL: see Formea CM, et al, 1021
Karpiuk E: see ACCP, et al, 1666
Kauffman CA: see Malani PN, et al, 690
Kays MB, Overholser BR, Lagvankar S, Goldman M, Sowinski KM: Effect of Ensure on the Oral Bioavailability of Gatifloxacin in Healthy Volunteers, 1530
Kays MB: see Overholser BR, et al, 1310
Kazi S: see Busti AJ, et al, 1566
Kennedy DH: see ACCP, et al, 1396
Kenton I: see Mohr JF, et al, 1303
Kephart G, Sketris IS, Bowles SK, Richard ME, Cooke CA: Impact of a Criteria-Based Reimbursement Policy on the Use of Respiratory Drugs Delivered by Nebulizer and Health Care Services Utilization in Nova Scotia, Canada, 1248
Kerr JR: Neonatal Effects of Breast Cancer Chemotherapy Administered During Pregnancy, 438
Kerzee JA: see Shanahan RL, et al, 345
Kesten S: see Covelli H, et al, 1708
Khakoo RA: see Slain D, et al, 165
Kimura K: see Kusaba T, et al, 52
Kirwin JL, Gören JL: Duloxetine: A Dual Serotonin-Norepinephrine Reuptake Inhibitor for Treatment of Major Depressive Disorder, 396
Kiser TH, Jung R, MacLaren R, Fish DN: Evaluation of Diagnostic Tests and Argatroban or Lepirudin Therapy in Patients with Suspected Heparin-Induced Thrombocytopenia, 1736
Klauck JA: see Sakai EM, et al, 1773
Klein LR: see Malani PN, et al, 690
Klepser DG: see Chrischilles EA, et al, 668
Kluger J: see Min B, et al, 1719
Kluger J: see Min B, et al, 654
Kluger J: see Perkerson KA, et al, 320
Knowles SR, Wong GA, Rahim SA, Binkley K, Phillips EJ, Shear NH: Hydrochlorothiazide-Induced Noncardiogenic Pulmonary Edema: An Under-recognized Yet Serious Adverse Drug Reaction, 1258
Kogut SJ, El-Maouche D, Abughosh SM: Decreased Persistence to Cholinesterase Inhibitor Therapy with Concomitant Use of Drugs That Can Impair Cognition, 1729
Kolade VO, Bosinski TJ, Ruffy EL: Acute Promyelocytic Leukemia After Iodine-131 Therapy for Graves' Disease, 1017
Kollef MH: see Micek ST, et al, 26
Kolor B: Patient Education and Treatment Strategies Implemented at a Pharmacist-Managed Hepatitis C Virus Clinic, 1230
Konno Y: see Kusaba T, et al, 52
Kontoyiannis DP: see Lionakis MS, et al, 1174
Krähenbühl S: see Egger SS, et al, 881
Krantz MJ, Coronel SM, Hiatt WR: Use of Ankle Brachial Index Screening for Selecting Patients for Antiplatelet Drug Therapy, 1826
Krantz MJ, Garcia JA, Mehler PS: Effects of Buprenorphine on Cardiac Repolarization in a Patient with Methadone-Related Torsade de Pointes, 611
Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH: Effects of Methadone on QT-Interval Dispersion, 1523
Ksenich RA: see Buck ML, et al, 1536
Kuboshima S: see Kusaba T, et al, 52
Kudis HA: Interviewing: Content versus Style, 635
Kukoyi O, Argo TR, Carnahan RM: Exacerbation of Panic Disorder with Rifampin Therapy in a Patient Receiving Citalopram, 435
Kusaba T, Konno Y, Hatta S, Fujino T, Yasuda T, Miura H, Sasaki H, Okabayashi J, Murao M, Sakurada T, Imai G, Shirai S, Kuboshima S, Shima Y, Ogimoto G, Sato T, Masuhara K, Kimura K: More Stable and Reliable Pharmacokinetics with Preprandial Administration of Cyclosporine Compared with Postprandial Administration in Patients with Refractory Nephrotic Syndrome, 52
Kuti JL, Horowitz S, Nightingale CH, Nicolau DP: Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem, 935
Kutscher EC: see Carnahan RM, et al, 1646

- L -

Lagvankar S: see Kays MB, et al, 1530
Lagvankar S: see Overholser BR, et al, 1310
Lalka D: see Slain D, et al, 165

Lande L: see Brucculeri M, et al, 119
LaPlante KL: see Rybak MJ, et al, 74
Larijani GE, Sharaf I, Warshal DP, Marr A, Gratz I, Goldberg ME: Pain Evaluation in Patients Receiving Intravenous Patient-Controlled Analgesia After Surgery, 1168
Lassen D: see Gleason PP, et al, 924
Lau AK: see Devlin JW, et al, 1348
Lea JW: see Stoner SC, et al, 1651
Lee P-H: see Wu F-LL, et al, 646
Leeds AL: see Inciardi JF, et al, 790
Leroy B: see Shi J, et al, 42
Lettieri SL: see Culhane NS, et al, 990
Levey AS: see Bailie GR, et al, 491
Levin A: see Shalansky SJ, et al, 1095
Lewis GM: see Evans M, et al, 1656
Lewis II JS, Boucher HW, Lubowski TJ, Ambegaonkar AJ, Day DL, Patterson TF: Cost Advantage of Voriconazole over Amphotericin B Deoxycholate for Primary Treatment of Invasive Aspergillosis, 839
Lewis JG: see Markowitz JS, et al, 1337
Lewis RE: see Lionakis MS, et al, 1174
Lilly CM: see Adams CD, et al, 765
Link BK: see Chrischilles EA, et al, 668
Linnebur SA: see ACCP, et al, 1396
Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP: Aspergillus Susceptibility Testing in Patients with Cancer and Invasive Aspergillosis: Difficulties in Establishing Correlation Between In Vitro Susceptibility Data and the Outcome of Initial Amphotericin B Therapy, 1174
Liu P-YY: see Chang C-M, et al, 831
Locke C, Ravnan SL, Patel R, Uchizono JA: Reduction in Warfarin Adverse Events Requiring Patient Hospitalization After Implementation of a Pharmacist-Managed Anticoagulation Service, 685
Lott RS: see Mayo JL, et al, 520
Louder A: see Guo JJ, et al, 1044
Lowery CM: see Krantz MJ, et al, 1523
Lu F-H: see Chang C-M, et al, 831
Lubowski TJ: see Lewis II JS, et al, 839
Lucas Jr BD: see Miller MG, et al, 847
Lunsford SL: see Stanley KM, et al, 1073
Lynch KJ: see Schonder KS, et al, 918
Lynch P: see Robertson SM, et al, 1068
Lyons RM: see Reese AM, et al, 1746

- M -

MacGregor RR: see Brady KA, et al, 10
Machado LS: see Fagan SC, et al, 387
MacLaren R, Sullivan PW: Pharmacoeconomic Modeling of Lorazepam, Midazolam, and Propofol for Continuous Sedation in Critically Ill Patients, 1319
MacLaren R: see Kiser TH, et al, 1736
MacLaren R: see Obritsch MD, et al, 1353
MacLaughlin AA: see MacLaughlin EJ, et al, 379
MacLaughlin EJ, MacLaughlin AA, Snella KA, Winston TS, Fike DS, Raehl CL: Osteoporosis Screening and Education in Community Pharmacies Using a Team Approach, 379
Madsen EM: see Shprecher AR, et al, 817
Magid DJ: see Raebel MA, et al, 1055
Mahadevia PJ: The Pocketbook: Pharmacoeconomic Issues Related to Intravenous Immunoglobulin Therapy, 94S
Mai T: see Havrda DE, et al, 303
Majumdar SR: Eurich DT, et al, 810
Malani PN, DePestel DD, Riddell IV J, Bickley S, Klein LR, Kauffman CA: Experience with Community-Based Amphotericin B Infusion Therapy, 690
Malik A, Capling R, Bastani B: Enoxaparin-Associated Retroperitoneal Bleeding in Two Patients with Renal Insufficiency, 769
Malone DC: see Joish VN, et al, 676
Mandell GL: Uptake, Transport, Delivery, and Intracellular Activity of Antimicrobial Agents, 130S
Mantadakis E, Cole PD, Kamen BA: High-Dose Methotrexate in Acute Lymphoblastic Leukemia: Where Is the Evidence for Its Continued Use?, 748
Maples HD: see Muldrew KM, et al, 893
Margolis MB: see Bridy-Pappas AE, et al, 1193
Marik PE: Propofol: An Immunomodulating Agent, 28S
Markantonis SL: see Giagoudakis G, et al, 18
Markowitz JS, DeVane CL, Lewis JG, Chavin KD, Wang J-S, Donovan JL: Effect of Ginkgo biloba Extract on Plasma Steroid Concentrations in Healthy Volunteers: A Pilot Study, 1337
Markson LE: see Allen-Ramey FC, et al, 1752
Marr A: see Larijani GE, et al, 1168
Martell BA: see Krantz MJ, et al, 1523
Martin CA: see Grim SA, et al, 253
Martin CP, Talbert RL: Aspirin Resistance: An Evaluation of Current Evidence and Measurement Methods, 942
Martin SJ: see Erstad BL, et al, 585
Massry SG: see Bailie GR, et al, 1687
Masuhara K: see Kusaba T, et al, 52
Matter CM: see Fischer LM, et al, 503
May DB: see Pope SD, et al, 1761
Mayo JL, Cahill GM, Lott RS: Conversion from Sustained-Release to Immediate-Release Bupropion: Patient Tolerability and Economic Impact, 520
McBride BF: see Min B, et al, 654
McCall KL, Scott JC, Anderson Jr HG: Retrospective Evaluation of a Possible Interaction Between Warfarin and Levofloxacin, 67
McCord AD: see ACCP, et al, 1396
McCoy RH: see Camamo JM, et al, 184
McKaveney TP: see Schonder KS, et al, 918
McKinnon PS: see Mohr JF, et al, 1303
Mehler PS: see Krantz MJ, et al, 611
Meier CR: see Fischer LM, et al, 503
Menajovsky LB: see DeEugenio DL, et al, 615
Meng F: see Mullins CD, et al, 660
Merenich JA: see Shanahan RL, et al, 345
Micek ST, Isakow W, Shannon W, Kollef MH: Predictors of Hospital Mortality for Patients with Severe Sepsis Treated with Drotrecogin alfa

(activated), 26
Milavetz G: see Barnett MJ, et al, 1550
Miller AL: see Patel NC, et al, 1242
Miller JG: see Stanley KM, et al, 1073
Miller MG, Lucas Jr BD, Papademetriou V, Elhabyan A: Aspirin Under Fire: Aspirin Use in the Primary Prevention of Coronary Heart Disease, 847
Miller MG, Mulligan T: Human Immunodeficiency Virus and Hypogonadal Bone Disease, 632
Miller SL: see ACCP, et al, 1396
Mills E: see van Heeswijk RPG, et al, 1725
Min B, Cios D, Kluger J, White CM: Absence of QTc-Interval–Prolonging or Hemodynamic Effects of a Single Dose of Bitter-Orange Extract in Healthy Subjects, 1719
Min B, McBride BF, Kardas MJ, Ismali A, Sinha V, Kluger J, White CM: Electrocardiographic Effects of an Ephedra-Free, Multicomponent Weight-Loss Supplement in Healthy Volunteers, 654
Mistry RB, Nahata MC: Ketamine for Conscious Sedation in Pediatric Emergency Care, 1104
Miura H: see Kusaba T, et al, 52
Mohler MJ: see Joish VN, et al, 676
Mohr JF, Hall AC, Ericsson CD, Ostrosky-Zeichner L: Fatal Amphotericin B Overdose Due to Administration of Nonlipid Formulation Instead of Lipid Formulation, 426
Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC: A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone, 1303
Montay G: see Shi J, et al, 42
Mooss AN: see Burns TL, et al, 1621
Morgan L: see Reese AM, et al, 1746
Motl SE, Baskin RC: Delayed-Onset Grade 4 Neutropenia Associated with Rituximab Therapy in a Patient with Lymphoma: Case Report and Literature Review, 1151
Moudgal VV: see Duggan JM, et al, 698
Mueller BA: see Overholser BR, et al, 1310
Muldrew KM, Maples HD, Stowe CD, Jacobs RF: Intravenous Voriconazole Therapy in a Preterm Infant, 893
Mulligan T: see Miller MG, et al, 632
Mullins CD, Shaya FT, Meng F, Wang J, Harrison D: Persistence, Switching, and Discontinuation Rates Among Patients Receiving Sertraline, Paroxetine, and Citalopram, 660
Muma BK: see Zarowitz BJ, et al, 1636
Murao M: see Kusaba T, et al, 52
Murray CK: see Chang NN, et al, 59

- N -

Nagle B: see Teagarden JR, et al, 1629
Nahata MC: see Benavides S, et al, 803
Nahata MC: see Mistry RB, et al, 1104
Nelson JE: see Turner RC, et al, 626
Newman N: see Phillips EM, et al, 1341
Ng TMH: see Arnold LM, et al, 904
Nickeleit V: see Joy MS, et al, 779
Nicolau DP: see Kuti JL, et al, 935
Niedermeier DM, Frei-Lahr DA, Hall PD: Treatment of Acute Myeloid Leukemia During the Second and Third Trimesters of Pregnancy, 1134
Nightingale CH: Future In Vitro and Animal Studies: Development of Pharmacokinetic and Pharmacodynamic Efficacy Predictors for Tissue-Based Antibiotics, 146S
Nightingale CH: see Kuti JL, et al, 935
Nissen LR: see Arnold LM, et al, 904
Nolan SF: see Self TH, et al, 526
Nuermberger E: Murine Models of Pneumococcal Pneumonia and Their Applicability to the Study of Tissue-Directed Antimicrobials, 134S
Nugent KM: see Perez-Verdia A, et al, 1271
Nutescu EA: see Wittkowsky AK, et al, 265

- O -

O'Connell MB: see ACCP, et al, 1396
O'Dell KM: see Jennings DL, et al, 1126
O'Neill JL, Flanagan PS, Zaleon CR, Copeland LA: Safety of Outpatient Dalteparin Therapy in Veterans with Mechanical Heart Valves, 1560
Obritsch MD, Fish DN, MacLaren R, Jung R: Nosocomial Infections Due to Multidrug-Resistant Pseudomonas aeruginosa: Epidemiology and Treatment Options, 1353
Obritsch MD: see Carnahan RM, et al, 1646
Oderda GM: see Shane-McWhorter L, et al, 96
Ogimoto G: see Kusaba T, et al, 52
Okabayashi J: see Kusaba T, et al, 52
Okhuysen PC: see Mohr JF, et al, 1303
Orensky IA, Holdford DA: Predictors of Noncompliance with Warfarin Therapy in an Outpatient Anticoagulation Clinic, 1801
Ostrosky-Zeichner L: see Mohr JF, et al, 426
Overholser BR, Kays MB, Lagvankar S, Goldman M, Mueller BA, Sowinski KM: Pharmacokinetics of Intravenously Administered Levofloxacin in Men and Women, 1310
Overholser BR: see Kays MB, et al, 1530
Owens Jr RC: Fluoroquinolone-Associated Dysglycemias: A Tale of Two Toxicities, 1291
Oyen L: see ACCP, et al, 1666
Ozet A: see Uner A, et al, 1011

- P -

Page II RL: see Ruscin JM, et al, 313
Pajoumand M: see Clifford TM, et al, 773
Papademetriou V: see Miller MG, et al, 847
Parrino TA: Controlled Trials to Improve Antibiotic Utilization: A Systematic Review of Experience, 1984–2004, 289
Pate GE: see Shalansky SJ, et al, 1095
Patel B: see Reese AM, et al, 1746
Patel NC, Crismon ML, Miller AL, Johnsrud MT: Drug Adherence: Effects of Decreased Visit Frequency on Adherence to Clozapine Therapy, 1242

Patel R: see Locke C, et al, 685
Patterson TF: see Lewis II JS, et al, 839
Pearson G: see Yamada C, et al, 110
Perez-Verdia A, Angulo F, Hardwicke FL, Nugent KM: Acute Cardiac Toxicity Associated with High-Dose Intravenous Methotrexate Therapy: Case Report and Review of the Literature, 1271
Perkerson KA, Gillespie EL, White CM, Kluger J, Takata H, Kardas M, Ismaili A, Coleman CI: Impact of Prophylactic Amiodarone on Length of Hospital Stay, Stroke, and Atrial Fibrillation After Cardiothoracic Surgery, 320
Peros E: see Derosa G, et al, 637
Peruzzi WT: Sleep in the Intensive Care Unit, 34S
Pestotnik SL: Expert Clinical Decision Support Systems to Enhance Antimicrobial Stewardship Programs: Insights from the Society of Infectious Diseases Pharmacists, 1116
Peterson EL: see Zarowitz BJ, et al, 1636
Peymann PJ: see Mohr JF, et al, 1303
Phillips DP, Jarvinen JR, Phillips RR: A Spike in Fatal Medication Errors at the Beginning of Each Month, 1
Phillips EJ: see Knowles SR, et al, 1258
Phillips EJ: see van Heeswijk RPG, et al, 1725
Phillips EM, Buchan DA, Newman N, Rajan A, Zia S: Low-Molecular-Weight Heparin May Alter Point-of-Care Assay for International Normalized Ratio, 1341
Phillips RR: see Phillips DP, et al, 1
Phillips SM: see Brouse SD, et al, 429
Piccinni MN: see Derosa G, et al, 637
Pieper JA: see Dornbrook-Lavender KA, et al, 325
Pizzimenti JJ, Daniel KP: Central Serous Chorioretinopathy After Epidural Steroid Injection, 1141
Pohl GM: see Van Brunt DL, et al, 1541
Pollock DM: see Fagan SC, et al, 387
Pope SD, Johnson MD, May DB: Pharmacotherapy for Human Immunodeficiency Virus–Associated Nephropathy, 1761
Postelnick MJ: see Robertson SM, et al, 1068
Powers JH: Microbiologic Surrogate End Points in Clinical Trials of Infectious Diseases: Example of Acute Otitis Media Trials, 109S
Prescott Jr WA, Johnson CE: Antiinflammatory Therapies for Cystic Fibrosis: Past, Present, and Future, 555
Pruchnicki MC: see Zillich AJ, et al, 123
Pucino F: see Chen JT, et al, 171

- Q, R -

Raebel MA, Witt DM, Carroll NM, Magid DJ: Warfarin Monitoring in Ambulatory Older Individuals Receiving Antimicrobial Therapy, 1055
Raehl CL: see MacLaughlin EJ, et al, 379
Raehl CL: see Rudd KM, et al, 1592
Ragucci KR, Fermo JD, Wessell AM, Chumney ECG: Effectiveness of Pharmacist-Administered Diabetes Mellitus Education and Management Services, 1809
Ragucci KR: see Starr JA, et al, 1030
Rahim SA: see Knowles SR, et al, 1258
Rajan A: see Phillips EM, et al, 1341
Rapp RP: Introduction to Antimicrobial Resistance: Insights into Control and Treatment of Complicated Infections supplement, 41S
Rapp RP: see Grim SA, et al, 253
Rasmussen LD: see Carnahan RM, et al, 1646
Ravnan SL: see Locke C, et al, 685
Raymo L: see Wolowich WR, et al, 1283
Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI: Low-Dose Vitamin K to Augment Anticoagulation Control, 1746
Regal RE: see Eschenauer G, et al, 630
Richard ME: see Kephart G, et al, 1248
Riddell IV J: see Malani PN, et al, 690
Riker RR, Fraser GL: Adverse Events Associated with Sedatives, Analgesics, and Other Drugs That Provide Patient Comfort in the Intensive Care Unit, 8S
Riker RR: see Fraser GL, et al, 19S
Rivkin AM, Chawla S: Epoetin alfa for the Treatment of Combination Therapy–Induced Hemolytic Anemia in Patients Infected with Hepatitis C Virus, 862
Roberts BT: see Turner RC, et al, 626
Robertson P: see Yamada C, et al, 110
Robertson SM, Scarsi KK, Postelnick MJ, Lynch P: Elevated Plasma Concentrations of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors in Patients Coinfected with Human Immunodeficiency Virus and Hepatitis B or C: Case Series and Literature Review, 1068
Rodriguez EG: see Zerumsky K, et al, 797
Rodriguez JC: see Wolowich WR, et al, 1283
Romain TM: see Zarowitz BJ, et al, 1636
Rosborough TK, Shepherd MF, Couch PL: Selecting an Equation to Estimate Glomerular Filtration Rate for Use in Renal Dosage Adjustment of Drugs in Electronic Patient Record Systems, 823
Roth MT, Andrus MR, Westman EC: Outcomes from an Outpatient Smoking-Cessation Clinic, 279
Rudd KM, Raehl CL, Bond CA, Abbruscato TJ, Stenhouse AC: Methods for Assessing Drug-Related Anticholinergic Activity, 1592
Ruffy EL: see Kolade VO, et al, 1017
Ruggiero II NJ: see DeEugenio DL, et al, 615
Ruscin JM, Page II RL, Yeager BF, Wallace JI: Tumor Necrosis Factor-α and Involuntary Weight Loss in Elderly, Community-Dwelling Adults, 313
Rybak MJ, LaPlante KL: Community-Associated Methicillin-Resistant Staphylococcus aureus: A Review, 74
Rychlik PG, Henry KS, Bussey HI: Duration of Treatment of Deep Vein Thrombosis: Time for a New Approach?, 1112
Rychly DJ, DiPiro JT: Infections Associated with Tumor Necrosis Factor-α Antagonists, 1181

- S -

Saadeh CE: Chemotherapy- and Radiotherapy-Induced Oral Mucositis: Review of Preventive Strategies and Treatment, 540
Sahloff EG: Current Issues in the Development of a

Vaccine to Prevent Human Immunodeficiency Virus: Insights from the Society of Infectious Diseases Pharmacists, 741
Sahloff EG: see Duggan JM, et al, 698
Sajjan SG: see Allen-Ramey FC, et al, 1752
Sakai EM, Connolly LA, Klauck JA: Inhalation Anesthesiology and Volatile Liquid Anesthetics: Focus on Isoflurane, Desflurane, and Sevoflurane, 1773
Sakurada T: see Kusaba T, et al, 52
Salvadeo S: see Derosa G, et al, 637
Salverson SM: see Graumlich JF, et al, 1296
Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP: Assessment of Adherence Measures with Different Stimulants Among Children and Adolescents, 909
Sandhoff BG: see Shanahan RL, et al, 345
Santos CA, Boullata JI: An Approach to Evaluating Drug-Nutrient Interactions, 1789
Sasaki H: see Kusaba T, et al, 52
Saseen JJ: see Zillich AJ, et al, 123
Sato T: see Kusaba T, et al, 52
Sawatzki MG: see Egger SS, et al, 881
Sawchuk RJ, Cheung BWY, Ji P, Cartier LL: Microdialysis Studies of the Distribution of Antibiotics into Chinchilla Middle Ear Fluid, 140S
Scarsi KK: see Robertson SM, et al, 1068
Schaad UB: Predictive Value of Double Tympanocentesis in Acute Otitis Media, 105S
Schellekens H: see Combe C, et al, 954
Schleis TG: The Process: New Methods of Purification and Viral Safety, 73S
Schlienger RG: see Fischer LM, et al, 503
Schofield RS: see Clark BM, et al, 756
Schonder KS, McKaveney TP, Lynch KJ: Retrospective Analysis of Hyperlipidemia Management in a Transplant Population, 918
Scott JC: see McCall KL, et al, 67
Scott SD: see Chrischilles EA, et al, 668
Segal JL: Immunoactivation and Altered Intercellular Communication Mediate the Pathophysiology of Spinal Cord Injury, 145
Seguin I: see van Heeswijk RPG, et al, 1725
Sekreta CM: see Wittkowsky AK, et al, 265
Self TH, Cross LB, Nolan SF, Weibel JB, Hilaire M, Franks AR, Finch CK, Tolley EA: Gender Differences in the Use of Peak Flow Meters and Their Effect on Peak Expiratory Flow, 526
Septimus E: see Mohr JF, et al, 1303
Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG: N-acetylcysteine for Prevention of Radiographic Contrast Material–Induced Nephropathy: Is the Intravenous Route Best?, 1095
Shamburek RD: see Chen JT, et al, 171
Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA: Low Myopathy Rates Associated with Statins as Monotherapy or Combination Therapy with Interacting Drugs in a Group Model Health Maintenance Organization, 345
Shane-McWhorter L, Oderda GM: Providing Diabetes Education and Care to Underserved Patients in a Collaborative Practice at a Utah Community Health Center, 96
Shannon W: see Micek ST, et al, 26
Sharaf I: see Larijani GE, et al, 1168
Shaya FT: see Mullins CD, et al, 660
Shear NH: see Knowles SR, et al, 1258
Shehab N, Sweet BV, Hogikyan ND: Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: A Review of the Literature, 977
Shepherd G: Adverse Effects Associated with Extra Doses of Bupropion, 1378
Shepherd MF: see Rosborough TK, et al, 823
Shepler BM: see Byrnes CA, et al, 709
Shetzline MA, Cohard-Radice M, Joelsson B: Ischemic Colitis, Irritable Bowel Syndrome, and Tegaserod—An Alternative Viewpoint, 1684
Shi J, Montay G, Leroy B, Bhargava VO: Effects of Itraconazole or Grapefruit Juice on the Pharmacokinetics of Telithromycin, 42
Shima Y: see Kusaba T, et al, 52
Shirai S: see Kusaba T, et al, 52
Shirazi F: see van Heeswijk RPG, et al, 1725
Shprecher AR, Cheng-Lai A, Madsen EM, Cohen HW, Sinnett MJ, Wong ST, Billett HH: Peak Antifactor Xa Activity Produced by Dalteparin Treatment in Patients with Renal Impairment Compared with Controls, 817
Sias JJ: see Anaya JP, et al, 86
Siegel J: The Product: All Intravenous Immunoglobulins Are Not Equivalent, 78S
Simpson KN: see Stanley KM, et al, 1073
Simpson SH: see Eurich DT, et al, 810
Sinha V: see Min B, et al, 654
Sinnett MJ: see Shprecher AR, et al, 817
Skae JR: see Culhane NS, et al, 990
Sketris IS: see Kephart G, et al, 1248
Skrepnek GH, Ballard EE: Cost-Efficacy of Imatinib versus Allogeneic Bone Marrow Transplantation with a Matched Unrelated Donor in the Treatment of Chronic Myelogenous Leukemia: A Decision-Analytic Approach, 325
Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D, Hobbs GR: Effect of High-Dose Vitamin C on the Steady-State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers, 165
Smith JC: see Straka RJ, et al, 360
Smith KM: see Whitby DH, et al, 411
Smith KP: see Aucoin RG, et al, 1277
Snella KA: see MacLaughlin EJ, et al, 379
Sowinski KM: see Kays MB, et al, 1530
Sowinski KM: see Overholser BR, et al, 1310
Spencer AP: see Bickford CL, et al, 1389
Spencer AP: see Stanley KM, et al, 1073
Splinter MY: see ACCP, et al, 1396
Stanley KM, Worrall CL, Lunsford SL, Simpson KN, Miller JG, Spencer AP: Experience with an Adult Alcohol Withdrawal Syndrome Practice Guideline in Internal Medicine Patients, 1073
Starr JA, Ragucci KR: Thrombocytopenia Associated

with Intravenous Ciprofloxacin, 1030
Stebelsky LA: see Zarowitz BJ, et al, 1636
Stein GE: Antimicrobial Resistance in the Hospital Setting: Impact, Trends, and Infection Control Measures, 44S
Steinmetz KL: see Zerumsky K, et al, 797
Stenhouse AC: see Rudd KM, et al, 1592
Sterling KL: see Van Brunt DL, et al, 1541
Sterling T: see ACCP, et al, 1396
Sternhagen V: see Curtis JM, et al, 876
Stoner SC, Lea JW, Wolf AL, Berges AA: Quetiapine Use in a Patient with Chronic Schizophrenia and Severe Parkinsonism, 1651
Stout DL, Fugate SE: Thiazolidinediones for Treatment of Polycystic Ovary Syndrome, 244
Stowe CD: see Muldrew KM, et al, 893
Straka RJ, Taheri R, Cooper SL, Smith JC: Achieving Cholesterol Target in a Managed Care Organization (ACTION) Trial, 360
Striet J: see Benavides S, et al, 803
Sudekum MJ: see ACCP, et al, 1666
Sullivan PW: see MacLaren R, et al, 1319
Sun PJ: see Van Brunt DL, et al, 1541
Sun S-W: see Wu F-LL, et al, 646
Sweet BV: see Shehab N, et al, 977
Szumita PM: see Adams CD, et al, 765

- T -

Taheri R: see Straka RJ, et al, 360
Takata H: see Perkerson KA, et al, 320
Talbert RL: see Martin CP, et al, 942
Tanios MA: see Devlin JW, et al, 1348
Teagarden JR, Nagle B, Aubert RE, Wasdyke C, Courtney P, Epstein RS: Dispensing Error Rate in a Highly Automated Mail-Service Pharmacy Practice, 1629
Thomas MC: see Erstad BL, et al, 585
Thompson BD: see Joy MS, et al, 779
Thomson LJ: see DeEugenio DL, et al, 615
Tolley EA: see Self TH, et al, 526
Toltzis P: Comparison of Amoxicillin with Alternative Agents for the Treatment of Acute Otitis Media in Children, 124S
Touchette DR: see Hartung DM, et al, 1329
Tredree RL: see Combe C, et al, 954
Trujillo TC: see Itkin YM, et al, 886
Tsai J-H, Yang P, Yen J-Y, Chen C-C, Yang M-J: Zotepine-Induced Catatonia as a Precursor in the Progression to Neuroleptic Malignant Syndrome, 1156
Tsai M-K: see Wu F-LL, et al, 646
Tsuyuki RT: see Yamada C, et al, 110
Turner RC, Nelson JE, Roberts BT, Gillam DM: Venlafaxine-Associated Interstitial Pneumonitis, 626

- U, V -

Uchizono JA: see Locke C, et al, 685
Uhlig K: see Bailie GR, et al, 491
Uner A, Ozet A, Arpaci F, Unsal D: Long-Term Clinical Outcome After Accidental Overdose of Multiple Chemotherapeutic Agents, 1011
Unsal D: see Uner A, et al, 1011
Van Brunt DL, Johnston JA, Ye W, Pohl GM, Sun PJ, Sterling KL, Davis ME: Predictors of Selecting Atomoxetine Therapy for Children with Attention-Deficit–Hyperactivity Disorder, 1541
Van Cott EM: see Arpino PA, et al, 157
van Heeswijk RPG, Cooper CL, Foster BC, Chauhan BM, Shirazi F, Seguin I, Phillips EJ, Mills E: Effect of High-Dose Vitamin C on Hepatic Cytochrome P450 3A4 Activity, 1725
VandenBussche HL: see Bestul MB, et al, 211
Varner D: see Chong PH, et al, 270
Vermeulen LC: see ACCP, et al, 1666
Voelker MD: see Chrischilles EA, et al, 668
Vu T: see Shalansky SJ, et al, 1095

- W -

Wallace JI: see Ruscin JM, et al, 313
Wang J: see Mullins CD, et al, 660
Wang J-S: see Markowitz JS, et al, 1337
Warmack S: see Amsden JR, et al, 191
Warshal DP: see Larijani GE, et al, 1168
Wasdyke C: see Teagarden JR, et al, 1629
Webb JG: see Shalansky SJ, et al, 1095
Weibel JB: see Self TH, et al, 526
Welage LS: see Erstad BL, et al, 585
Wendel C: see Joish VN, et al, 676
Wermeling DP: Ziconotide, an Intrathecally Administered N-Type Calcium Channel Antagonist for the Treatment of Chronic Pain, 1084
Wesley R: see Chen JT, et al, 171
Wessell AM: see ACCP, et al, 1396
Wessell AM: see Ragucci KR, et al, 1809
Westman EC: see Roth MT, et al, 279
Whitby DH, Smith KM: The Use of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Women Who Are Breastfeeding, 411
White CM: see Coleman CI, et al, 448
White CM: see Min B, et al, 1719
White CM: see Min B, et al, 654
White CM: see Perkerson KA, et al, 320
Williams C: see Gleason PP, et al, 924
Williamson TE: see Darkow T, et al, 511
Wilson G: see Chant C, et al, 352
Wilson JP: see Sanchez RJ, et al, 909
Wilson TW: see Blackburn DF, et al, 1035
Winston TS: see MacLaughlin EJ, et al, 379
Witt DM: see Raebel MA, et al, 1055
Wittbrodt ET: Daily Interruption of Continuous Sedation, 3S
Wittkowsky AK, Sekreta CM, Nutescu EA, Ansell J: Barriers to Patient Self-Testing of Prothrombin Time: National Survey of Anticoagulation Practitioners, 265
Wolf AL: see Stoner SC, et al, 1651
Wolowich WR, Raymo L, Rodriguez JC: Problems with the Use of the Modified Diet in Renal Disease Formula to Estimate Renal Function, 1283
Wong GA: see Knowles SR, et al, 1258

Wong L: see Jaskiewicz AD, et al, 1820
Wong S-F, Chan HO: Effects of a Formulary Change from Granulocyte Colony-Stimulating Factor to Granulocyte-Macrophage Colony-Stimulating Factor on Outcomes in Patients Treated with Myelosuppressive Chemotherapy, 372
Wong ST: see Shprecher AR, et al, 817
Wooldridge P: see Buck ML, et al, 1536
Worrall CL: see Stanley KM, et al, 1073
Wu C-F: see Chang C-M, et al, 831
Wu F-LL, Tsai M-K, Chen RR-L, Sun S-W, Huang J-D, Hu R-H, Chen K-H, Lee P-H: Effects of Calcineurin Inhibitors on Sirolimus Pharmacokinetics During Staggered Administration in Renal Transplant Recipients, 646

- Y, Z -

Yamada C, Johnson JA, Robertson P, Pearson G, Tsuyuki RT: Long-Term Impact of a Community Pharmacist Intervention on Cholesterol Levels in Patients at High Risk for Cardiovascular Events: Extended Follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus), 110
Yang M-J: see Tsai J-H, et al, 1156
Yang P: see Tsai J-H, et al, 1156
Yang Y-C: see Chang C-M, et al, 831
Yang Y-HK: see Chang C-M, et al, 831
Yasuda T: see Kusaba T, et al, 52
Ye W: see Van Brunt DL, et al, 1541
Yeager BF: see Ruscin JM, et al, 313
Yen J-Y: see Tsai J-H, et al, 1156
Zaleon CR: see O'Neill JL, et al, 1560
Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL: Reduction of High-Risk Polypharmacy Drug Combinations in Patients in a Managed Care Setting, 1636
Zerumsky K, Steinmetz KL, Handler SM, Rodriguez EG: Pharmacist Detection of Peripheral Arterial Disease Through the Use of a Handheld Doppler, 797
Zia S: see Phillips EM, et al, 1341
Zillich AJ, Saseen JJ, DeHart RM, Dumo P, Grabe DW, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki MC, Joy MS: Caring for Patients with Chronic Kidney Disease: A Joint Opinion of the Ambulatory Care and the Nephrology Practice and Research Networks of the American College of Clinical Pharmacy, 123

Index to Volume 25

Subject Index

- A -

ACCP PRN opinion paper: caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the ACCP, 123

ACCP, annual meeting, abstracts and index of authors, 1431

ACCP, 2005 spring practice and research forum, abstracts and index of authors, 451

Acute respiratory distress syndrome, retrospective evaluation of inhaled prostaglandins in patients with, 184

Adherence and viral load response in patients infected with human immunodeficiency virus, assessing the utility of a community pharmacy refill record as a measure of, 790

Adverse drug reactions among first-visit elderly outpatients, use of the Beers criteria to predict, 831

Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit, 8S

Alcohol consumption, enhanced antithrombotic effect of warfarin associated with low-dose, 303

Alcohol withdrawal syndrome practice guideline in internal medicine patients, experience with an adult, 1073

Aldosterone receptor antagonism in heart failure, 1126

Allergy history, blood culture and susceptibility results and, do not influence fluoroquinolone use in the treatment of community-acquired pneumonia, 59

Allogeneic bone marrow transplantation with a matched unrelated donor, cost-efficacy of imatinib versus, in the treatment of chronic myelogenous leukemia: a decision-analytic approach, 325

American College of Clinical Pharmacy Position Statement: guidelines for therapeutic interchange—2004, 1666

American College of Clinical Pharmacy White Paper: pharmacy practice, research, education, and advocacy for older adults, 1396

Amiodarone use in patients with documented allergy to iodine-containing compounds, 429

Amiodarone, impact of prophylactic, on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery, 320

Amoxicillin, comparison of, with alternative agents for the treatment of acute otitis media in children, 124S

Amphotericin B deoxycholate for primary treatment of invasive aspergillosis, cost advantage of voriconazole over, 839

Amphotericin B infusion therapy, experience with community-based, 690

Amphotericin B overdose, fatal, due to administration of nonlipid formulation instead of lipid formulation, 426

Amphotericin B therapy, aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial, 1174

Anabolic steroids, dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and, 756

Analgesia, pain evaluation in patients receiving intravenous patient-controlled, after surgery, 1168

Analgesics, sedatives, and other drugs that provide patient comfort in the intensive care unit, adverse events associated with, 8S

Anesthesiology, inhalation, and volatile liquid anesthetics: focus on isoflurane, desflurane, and sevoflurane, 1773

Angiotensin II interruption, protective effects of, evidence for antiinflammatory actions, 1213

Angiotensin II receptor blockers, can the renin-angiotensin system protect against stroke? A focus on, 531

Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus, 1602

Animal studies, future in vitro and, development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics, 146S

Ankle brachial index screening, use of, for selecting patients for antiplatelet drug therapy, an alternative viewpoint, 1826

Ankle brachial index screening, use of, for selecting patients for antiplatelet drug therapy, a reply to an alternative viewpoint, 1827

Antibiotic lock technique: review of the literature, 211

Antibiotic therapy, pharmacodynamics and the prediction of efficacy in short-course, pediatric studies to validate the model, 159S

Antibiotic utilization, controlled trials to improve, a systematic review of experience, 1984–2004, 289

Antibiotics, future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based, 146S

Antibiotics, microdialysis studies of the distribution of, into chinchilla middle ear fluid, 140S

Anticholinergic activity, methods for assessing drug-related, 1592

Anticoagulation control, low-dose vitamin K to augment, 1746

Antifactor Xa activity, peak, produced by dalteparin treatment in patients with renal impairment compared with controls, 817
Antiinflammatory and immunomodulating therapy, effects of perioperative, on surgical wound healing, 1566
Antiinflammatory therapies for cystic fibrosis: past, present, and future, 55S
Antimicrobial agents, uptake, transport, delivery, and intracellular activity of, 130S
Antimicrobial armamentarium, the, evaluating current and future treatment options, 55S
Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures, 44S
Antimicrobial stewardship programs, expert clinical decision support systems to enhance: insights from the Society of Infectious Diseases Pharmacists, 1116
Antimicrobial therapy, warfarin monitoring in ambulatory older individuals receiving, 1055
Antiplatelet drug resistance: not ready for prime time, 1621
Antiplatelet drug therapy, use of ankle brachial index screening for selecting patients for, an alternative viewpoint, 1826
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome, 637
Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia, 1383
Argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia, evaluation of diagnostic tests and, 1736
Argatroban to warfarin, use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from, 157
Arterial disease, pharmacist detection of peripheral, through the use of a handheld Doppler, 797
Aspergillosis, cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive, 839
Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy, 1174
Aspirin resistance: an evaluation of current evidence and measurement methods, 942
Aspirin under fire: aspirin use in the primary prevention of coronary heart disease, 847
Asthma or chronic obstructive pulmonary disease, beta-blocker therapy in veterans with, 1550
Asthma-related health care resource use among patients starting fluticasone or montelukast therapy, 1752
Atomoxetine therapy for children with attention-deficit–hyperactivity disorder, predictors of selecting, 1541
Atorvastatin, effects of, on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis, 335
Atrial fibrillation, effect of access to anticoagulation management services on warfarin use in patients with, 1062
Atrial fibrillation, impact of prophylactic amiodarone on length of hospital stay, stroke, and, after cardiothoracic surgery, 320
Atrial fibrillation, lone, associated with creatine monohydrate supplementation, 762
Attention-deficit–hyperactivity disorder, predictors of selecting atomoxetine therapy for children with, 1541
Automated mail-service pharmacy practice, dispensing error rate in a highly, 1629
Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome, 765
Azithromycin-warfarin interaction: are we fishing with a red herring?, 630

- B -

Bacterial, rickettsial, spirochetal, and protozoal infectious diseases, tick-borne, in the United States: a comprehensive review, 191
Beers criteria, use of the, to predict adverse drug reactions among first-visit elderly outpatients, 831
Beta-blocker therapy in veterans with asthma or chronic obstructive pulmonary disease, 1550
Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature, 1389
Bispectral index monitoring in the intensive care unit provides more signal than noise, 19S
Bispectral index monitoring in the intensive care unit, 1681
Bitter-orange extract, absence of QTc-interval–prolonging or hemodynamic effects of a single dose of, in healthy subjects, 1719
Bleeding, enoxaparin-associated retroperitoneal, in two patients with renal insufficiency, 769
Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia, 59
Bone cement, acute renal failure after placement of tobramycin-impregnated, in an infected total knee arthroplasty, 876
Bone disease, human immunodeficiency virus and hypogonadal, 632
Bone metabolism and disease in chronic kidney disease, clinical practice guidelines for, an overview, 1687
Bortezomib therapy for plasma cell leukemia, tumor lysis syndrome after, 1820
Bradycardia, early-onset pentamidine-associated second-degree heart block and sinus, case report and review of the literature, 899
Breast milk, levofloxacin secretion in: a case report, 116
Breastfeeding, the use of tricyclic antidepressants and selective serotonin reuptake inhibitors in women

who are, 411
Buprenorphine, effects of, on cardiac repolarization in a patient with methadone-related torsade de pointes, 611
Bupropion, adverse effects associated with extra doses of, 1378
Bupropion, conversion from sustained-release to immediate-release: patient tolerability and economic impact, 520

- C -

Calcineurin inhibitor–induced nephrotoxicity and renal expression of p-glycoprotein, 779
Calcineurin inhibitors, altered cytochrome P450 metabolism of, case report and review of the literature, 1021
Calcineurin inhibitors, effects of, on sirolimus pharmacokinetics during staggered administration in renal transplant recipients, 646
Calcium channel antagonist, ziconotide, an intrathecally administered N-type, for the treatment of chronic pain, 1084
Cancer chemotherapy administered during pregnancy, neonatal effects of breast, 438
Cardiac toxicity, acute, associated with high-dose intravenous methotrexate therapy: case report and review of the literature, 1271
Cardiomyopathy, dilated, and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids, 756
Cardiovascular morbidity associated with nonadherence to statin therapy, 1035
Catatonia, zotepine-induced, as a precursor in the progression to neuroleptic malignant syndrome, 1156
Ceftazidime and meropenem, comparison of pharmacodynamic target attainment between healthy subjects and patients for, 935
Ceftriaxone, biliary sludge and hyperbilirubinemia associated with, in an adult: case report and review of the literature, 1389
Ceftriaxone, gatifloxacin, and levofloxacin, pharmacodynamic analysis of, against Streptococcus pneumoniae with the use of Monte Carlo simulation, 1161
Ceftriaxone, gatifloxacin, levofloxacin, or ciprofloxacin, a retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving, 1303
Celecoxib-induced nephrotoxicity in a renal transplant recipient, 773
Cerebrospinal fluid, stavudine entry into, after single and multiple doses in patients infected with human immunodeficiency virus, 10
Chemotherapeutic agents, long-term clinical outcome after accidental overdose of multiple, 1011
Chinchilla middle ear fluid, microdialysis studies of the distribution of antibiotics into, 1405
Cholesterol levels, community pharmacist intervention, long-term impact of, in patients at high risk for cardiovascular events (SCRIP-PLUS), 110
Cholesterol phenotype, effects of atorvastatin on low-density lipoprotein, and C-reactive protein levels in patients undergoing long-term dialysis, 335
Cholesterol target, achieving, in a managed care organization (ACTION) trial, 360
Cholinesterase inhibitor therapy, decreased persistence to, with concomitant use of drugs that can impair cognition, 1729
Chorioretinopathy, central serous, after epidural steroid injection, 1141
Chromogenic factor X assay, use of the, to predict the international normalized ratio in patients transitioning from argatroban to warfarin, 157
Chronic obstructive pulmonary disease, absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with, 1708
Chronic obstructive pulmonary disease, beta-blocker therapy in veterans with asthma or, 1550
Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature, 977
Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis, 709
Ciprofloxacin, gatifloxacin, levofloxacin, or ceftriaxone, a retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving, 1303
Ciprofloxacin, thrombocytopenia associated with intravenous, 1030
Citalopram, exacerbation of panic disorder with rifampin therapy in a patient receiving, 435
Citalopram, sertraline, and paroxetine, persistence, switching, and discontinuation rates among patients receiving, 660
Citalopram-induced junctional bradycardia, reversal of, with intravenous sodium bicarbonate, 119
Clinical decision support systems, expert, to enhance antimicrobial stewardship programs: insights from the Society of Infectious Diseases Pharmacists, 1116
Clozapine therapy, drug adherence: effects of decreased visit frequency on adherence to, 1242
Cognition, decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair, 1729
Colitis, tegaserod-associated ischemic, 620
Collaborative practice, providing diabetes education and care to underserved patients in a Utah community health center, 96
Community-associated methicillin-resistant Staphylococcus aureus: a review, 74
Conscious sedation in pediatric emergency care, ketamine for, 1104
Coronary heart disease, aspirin under fire: aspirin use in the primary prevention of, 847
C-reactive protein levels, effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) on high-sensitivity, 1365
C-reactive protein levels, effects of atorvastatin on

low-density lipoprotein cholesterol phenotype and, in patients undergoing long-term dialysis, 335
Creatinine clearance versus glomerular filtration rate for the use of renal drug dosing in patients with kidney dysfunction, 1286
Cyclooxygenase-2 inhibitor prior authorization program, medical and pharmacy expenditures after implementation of a, 924
Cyclosporine, more stable and reliable pharmacokinetics with preprandial administration of, compared with postprandial administration in patients with refractory nephrotic syndrome, 52
Cystic fibrosis, antiinflammatory therapies for, past, present, and future, 555
Cytochrome P450 3A4 activity, effect of high-dose vitamin C on hepatic, 1725

- D -

Dalteparin therapy in a patient with impaired renal function, life-threatening hemorrhage after, 881
Dalteparin therapy in veterans with mechanical heart valves, safety of outpatient, 1560
Dalteparin treatment, peak antifactor Xa activity produced by, in patients with renal impairment compared with controls, 817
Deep vein thrombosis, duration of treatment of, time for a new approach?, 1112
Depressive disorder, duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major, 396
Desflurane, and sevoflurane, inhalation anesthesiology and volatile liquid anesthetics: focus on isoflurane, 1773
Diabetes education and care, providing, to underserved patients in a collaborative practice at a Utah community health center, 96
Diabetes mellitus and metabolic syndrome, antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy, in patients with type 2, 637
Diabetes mellitus education and management services, effectiveness of pharmacist-administered, 1809
Diabetes mellitus severity index, development and validation of a, a risk-adjustment tool for predicting health care resource use and costs, 676
Diabetes mellitus, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2, 1602
Diabetes mellitus, efficacy and safety of hypoglycemic drugs in children with type 2, 803
Diabetes mellitus, secondary failure rates associated with metformin and sulfonylurea therapy for type 2, 810
Diagnostic tests, evaluation of, and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia, 1736
Diclofenac, indomethacin, and ibuprofen, relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs, 18
Dispensing error rate in a highly automated mail-service pharmacy practice, 1629
Doppler, pharmacist detection of peripheral arterial disease through the use of a handheld, 797
Drotrecogin alfa (activated), predictors of hospital mortality for patients with severe sepsis treated with, 26
Drotrecogin alfa (activated)–induced prolongation of activated partial thromboplastin time in a patient with severe sepsis, challenge and rechallenge, 1147
Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy, 1242
Drug combinations, reduction of high-risk polypharmacy, in patients in a managed care setting, 1636
Drug dosing in patients with kidney dysfunction, creatinine clearance versus glomerular filtration rate for the use of renal, 1286
Drug resistance, antiplatelet, not ready for prime time, 1621
Drug-nutrient interactions, an approach to evaluating, 1789
Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder, 396
Dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone, a retrospective, comparative evaluation of, 1303
Dysglycemias, fluoroquinolone-associated: a tale of two toxicities, editorial, 1291
Dystonia, probable topical permethrin-induced neck, 448

- E -

Electrocardiographic effects of an ephedra-free, multicomponent weight-loss supplement in healthy volunteers, 654
Electrocardiographic findings, absence of, and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease, 1708
Enoxaparin-associated retroperitoneal bleeding in two patients with renal insufficiency, 769
Ensure, effect of, on the oral bioavailability of gatifloxacin in healthy volunteers, 1530
Ephedra, gamma-hydroxybutyrate, and anabolic steroids, dilated cardiomyopathy and acute liver injury associated with combined use of, 756
Epidermal necrolysis, toxic, probable vancomycin-associated, 308
Epinephrine overdose–associated hypokalemia and rhabdomyolysis in a newborn, 1266
Epoetin alfa for the treatment of combination therapy–induced hemolytic anemia in patients infected with hepatitis C virus, 862
Epoetins, biosimilar, an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins, 954

Equation to estimate glomerular filtration rate for use in renal dosage adjustment of drugs in electronic patient record systems, selecting an, 823
Ethanol intoxication, acute, after consumption of hairspray, 1646
Extracorporeal membrane oxygenation, comparison of methods for intravenous infusion of fat emulsion during, 1536

- F -

Fat emulsion, comparison of methods for intravenous infusion of, during extracorporeal membrane oxygenation, 1536
Fatal medication errors, a spike in, at the beginning of each month, 1
Fibrosis, azacitidine-induced interstitial and alveolar, in a patient with myelodysplastic syndrome, 765
Fluoroquinolone use in the treatment of community-acquired pneumonia, blood culture and susceptibility results and allergy history do not influence, 59
Fluoroquinolone-associated dysglycemias: a tale of two toxicities, editorial, 1291
Fluorouracil therapy, increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of, 442
Fluticasone or montelukast therapy, asthma-related health care resource use among patients starting, 1752

- G -

Gabapentin-induced neurologic toxicities, 1817
Gamma-hydroxybutyrate, and anabolic steroids, dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, 756
Gatifloxacin or levofloxacin therapy, hypoglycemia in inpatients after, nested case-control study, 1296
Gatifloxacin, ceftriaxone, and levofloxacin, pharmacodynamic analysis of, against Streptococcus pneumoniae with the use of Monte Carlo simulation, 1161
Gatifloxacin, effect of Ensure on the oral bioavailability of, in healthy volunteers, 1530
Gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone, a retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving, 1303
Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety, 717
Gender differences in the use of peak flow meters and their effect on peak expiratory flow, 526
Ginkgo biloba extract, effect of, on plasma steroid concentrations in healthy volunteers: a pilot study, 1337
Glimepiride-metformin combination therapy, antithrombotic effects of rosiglitazone-metformin versus, in patients with type 2 diabetes mellitus and metabolic syndrome, 637
Glomerular filtration rate for use in renal dosage adjustment of drugs in electronic patient record systems, selecting an equation to estimate, 823
Glomerular filtration rate versus creatinine clearance for the use of renal drug dosing in patients with kidney dysfunction, 1286
Gram-positive resistance: pathogens, implications, and treatment options, insights from the Society of Infectious Diseases Pharmacists, 1001
Granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor, effects of a formulary change from, on outcomes in patients treated with myelosuppressive chemotherapy, 372
Granulocyte-macrophage colony-stimulating factor to granulocyte colony-stimulating factor, effects of a formulary change from, on outcomes in patients treated with myelosuppressive chemotherapy, 372
Grapefruit juice or itraconazole, effects of, on the pharmacokinetics of telithromycin, 42

- H -

Hairspray, acute ethanol intoxication after consumption of, 1646
Heart block and sinus bradycardia, early-onset pentamidine-associated second-degree, case report and review of the literature, 899
Heart failure associated with thiazolidinedione therapy, risk of hospitalization for, a Medicaid claims–based case-control study, 1329
Heart failure, aldosterone receptor antagonism in, 1126
Hemodialysis, cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving, 709
Hemolytic anemia in patients infected with hepatitis C virus, epoetin alfa for the treatment of combination therapy–induced, 862
Hemorrhage, life-threatening, after dalteparin therapy in a patient with impaired renal function, 881
Heparin, low-molecular-weight, may alter point-of-care assay for international normalized ratio, 1341
Heparin-induced thrombocytopenia, argatroban and lepirudin requirements in a 6-year-old patient with, 1383
Heparin-induced thrombocytopenia, early-onset, after a 165-day heparin-free interval: case report and review of the literature, 615
Heparin-induced thrombocytopenia, evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected, 1736
Hepatitis B or C, elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and, case series and literature review, 1068
Hepatitis C virus clinic, patient education and treatment strategies implemented at a pharmacist-managed, 1230
Hepatitis C virus, epoetin alfa for the treatment of combination therapy–induced hemolytic anemia in

patients infected with, 862
Highly active antiretroviral therapy, use of, in patients with renal insufficiency, 698
Human immunodeficiency virus, stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with, 10
Human immunodeficiency virus and hepatitis B or C, elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with, case series and literature review, 1068
Human immunodeficiency virus and hypogonadal bone disease, 632
Human immunodeficiency virus infection, the use of interleukin-2 in, 86
Human immunodeficiency virus, acute pancreatitis associated with different combination therapies in patients infected with, 1044
Human immunodeficiency virus, assessing the utility of a community pharmacy refill record as a measure of adherence and viral load response in patients infected with, 790
Human immunodeficiency virus, current issues in the development of a vaccine to prevent, insights from the Society of Infectious Diseases Pharmacists, 741
Human immunodeficiency virus–associated nephropathy, pharmacotherapy for, 1761
Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction, 1258
Hyperbilirubinemia and biliary sludge, associated with ceftriaxone in an adult: case report and review of the literature, 1389
Hypercholesterolemia, rosuvastatin for the treatment of, 990
Hyperglycemia and infection in critically ill patients, relationship between, 963
Hyperlipidemia management in a transplant population, retrospective analysis of, 918
Hyperlipidemia, meta-analysis of natural therapies for: plant sterols and stanols versus policosanol, 171
Hyperparathyroidism, cinacalcet: a new treatment for secondary, in patients receiving hemodialysis, 709
Hypertriglyceridemia and pancreatitis, propofol-associated, in the intensive care unit: an analysis of frequency and risk factors, 1348
Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study, 1296
Hypoglycemic drugs in children with type 2 diabetes mellitus, efficacy and safety of, 803
Hypokalemia and rhabdomyolysis in a newborn, epinephrine overdose–associated, 1266

- I -

Ibuprofen, indomethacin, and diclofenac, relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs, 18
Imatinib versus allogeneic bone marrow transplantation, cost-efficacy of, with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach, 325
Immunoactivation and altered intercellular communication mediate the pathophysiology of spinal cord injury, 145
Immunoglobulin, intravenous, –associated acute renal failure: case series and literature review, 886
Immunoglobulins, the patient: emerging clinical applications of intravenous immunoglobulin, 85S
Immunoglobulins, the pocketbook: pharmacoeconomic issues related to intravenous immunoglobulin therapy, 94S
Immunoglobulins, the process: new methods of purification and viral safety, 73S
Immunoglobulins, the product: all intravenous immunoglobulins are not equivalent, 78S
Immunomodulating therapy, effects of perioperative antiinflammatory and, on surgical wound healing, 1566
In vitro and animal studies, future, development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics, 146S
Indinavir, effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor, in healthy volunteers, 165
Indomethacin, diclofenac, and ibuprofen, relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs, 18
Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics, 150S
Infection, relationship between hyperglycemia and, in critically ill patients, 963
Infections associated with tumor necrosis factor-alpha antagonists, 1181
Insulin infusion nomogram, validation of an, for intensive glucose control in critically ill patients, 352
Intensive care unit pharmacology—2004, key articles and guidelines relative to, 585
Intensive care unit, adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the, 8S
Intensive care unit, sleep in the, 34S
Interleukin-2, the use of, in human immunodeficiency virus infection, 86
International normalized ratio, increase in, after smoking cessation in a patient receiving warfarin, 1656
International normalized ratio, use of the chromogenic factor X assay to predict the, in patients transitioning from argatroban to warfarin, 157
Interviewing: content versus style, 635
Intracellular activity, uptake, transport, delivery, and, of antimicrobial agents, 130S
Iodine-131 therapy for Graves' disease, acute promyelocytic leukemia after, 1017
Isoflurane, desflurane, and sevoflurane, inhalation anesthesiology and volatile liquid anesthetics: focus

on, 1773
Itraconazole or grapefruit juice, effects of, on the pharmacokinetics of telithromycin, 42

- K -

Ketamine for conscious sedation in pediatric emergency care, 1104
Key articles and guidelines relative to intensive care unit pharmacology—2004, 585
Kidney disease, ACCP PRN opinion paper: caring for patients with chronic, a joint opinion of the ambulatory care and the nephrology practice and research networks of the ACCP, 123
Kidney disease, clinical practice guidelines for bone metabolism and disease in chronic, an overview, 1687
Kidney disease, clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic, 491
Kidney dysfunction, creatinine clearance versus glomerular filtration rate for the use of renal drug dosing in patients with, 1286

- L -

Lepirudin and argatroban, requirements in a 6-year-old patient with heparin-induced thrombocytopenia, 1383
Lepirudin therapy, evaluation of diagnostic tests and argatroban or, in patients with suspected heparin-induced thrombocytopenia, 1736
Leukemia, acute promyelocytic, after iodine-131 therapy for Graves' disease, 1017
Leukemia, cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous: a decision-analytic approach, 325
Leukemia, high-dose methotrexate in acute lymphoblastic, where is the evidence for its continued use?, 748
Leukemia, treatment of acute myeloid, during the second and third trimesters of pregnancy, 1134
Levofloxacin and warfarin, retrospective evaluation of a possible interaction between, 67
Levofloxacin or gatifloxacin therapy, hypoglycemia in inpatients after, nested case-control study, 1296
Levofloxacin secretion in breast milk: a case report, 116
Levofloxacin, ceftriaxone, and gatifloxacin, pharmacodynamic analysis of, against Streptococcus pneumoniae with the use of Monte Carlo simulation, 1161
Levofloxacin, gatifloxacin, ciprofloxacin, or ceftriaxone, a retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving, 1303
Levofloxacin, pharmacokinetics of intravenously administered, in men and women, 1310
Liver injury, dilated cardiomyopathy and acute, associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids, 756
Lone creatine monohydrate supplementation, atrial fibrillation associated with, 762
Lorazepam, midazolam, and propofol for continuous sedation in critically ill patients, pharmacoeconomic modeling of, 1319
Low-molecular-weight heparin may alter point-of-care assay for international normalized ratio, 1341
Lymphoma, delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with, case report and literature review, 1151
Lymphoma, neutropenia-related inpatient costs, effect of clinical characteristics on, among newly diagnosed non-Hodgkin's cases during first-course chemotherapy, 668

- M -

Macrolide and macrolide-like class of antibiotics, infection site concentrations: their therapeutic importance and the, 150S
Managed care setting, reduction of high-risk polypharmacy drug combinations in patients in a, 1636
Medication errors, a spike in fatal, at the beginning of each month, 1
Meropenem, comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and, 935
Metabolic syndrome, antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and, 637
Metformin and sulfonylurea therapy, secondary failure rates associated with, for type 2 diabetes mellitus, 810
Metformin-rosiglitazone versus glimepiride-metformin combination therapy, antithrombotic effects of, in patients with type 2 diabetes mellitus and metabolic syndrome, 637
Methadone, effects of, on QT-interval dispersion, 1523
Methadone-related torsade de pointes, effects of buprenorphine on cardiac repolarization in a patient with, 611
Methicillin-resistant Staphylococcus aureus, community-associated: a review, 74
Methicillin-resistant Staphylococcus aureus, trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by, 253
Methotrexate therapy, acute cardiac toxicity associated with high-dose intravenous, case report and review of the literature, 1271
Methotrexate, high-dose, in acute lymphoblastic leukemia: where is the evidence for its continued use?, 748
Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials, 109S
Microdialysis studies of the distribution of antibiotics into chinchilla middle ear fluid, 140S
Midazolam, lorazepam, and propofol for continuous sedation in critically ill patients, pharmacoeconomic

modeling of, 1319
Modified diet in renal disease formula to estimate renal function, problems with the use of the, 1283
Monte Carlo simulation, pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of, 1161
Montelukast therapy, asthma-related health care resource use among patients starting fluticasone or, 1752
Morphine, study to evaluate the analgesic and hemodynamic effects of a single dose of, —an alternative viewpoint, 1288
Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction, 904
Mucositis, chemotherapy- and radiotherapy-induced oral: review of preventive strategies and treatment, 540
Murine models of pneumococcal pneumonia and their applicability to the study of tissue-directed antimicrobials, 134S
Myelodysplastic syndrome, azacitidine-induced interstitial and alveolar fibrosis in a patient with, 765
Myocardial infarction, current use of nonsteroidal antiinflammatory drugs and the risk of acute, 503
Myopathy, low rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization, 345

- N -

N-acetylcysteine for prevention of radiographic contrast material–induced nephropathy: is the intravenous route best?, 1095
Natural therapies for hyperlipidemia, meta-analysis of: plant sterols and stanols versus policosanol, 171
Neonatal effects of breast cancer chemotherapy administered during pregnancy, 438
Nephrology, clinical practice guidelines in: evaluation, classification, and stratification of chronic kidney disease, 491
Nephropathy associated with type 2 diabetes mellitus, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of, 1602
Nephropathy, N-acetylcysteine for prevention of radiographic contrast material–induced, is the intravenous route best?, 1095
Nephropathy, pharmacotherapy for human immunodeficiency virus–associated, 1761
Nephrotoxicity, calcineurin inhibitor–induced, and renal expression of p-glycoprotein, 779
Nephrotoxicity, celecoxib-induced, in a renal transplant recipient, 773
Neuroleptic malignant syndrome, zotepine-induced catatonia as a precursor in the progression to, 1156
Neurologic toxicities, gabapentin-induced, 1817
Neutropenia, delayed-onset grade 4, associated with rituximab therapy in a patient with lymphoma: case report and literature review, 1151
Neutropenia-related inpatient costs, effect of clinical characteristics on, among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy, 668
Noncompliance, predictors of, with warfarin therapy in an outpatient anticoagulation clinic, 1801
Nonsteroidal antiinflammatory drugs, current use of, and the risk of acute myocardial infarction, 503
Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options, 1353
Nutrient-drug interactions, an approach to evaluating, 1789

- O -

Older adults, American College of Clinical Pharmacy White Paper: pharmacy practice, research, education, and advocacy for, 1396
Osteoporosis and statins: a clinical review, 228
Osteoporosis screening and education in community pharmacies using a team approach, 379
Osteoporosis, treatment of postmenopausal, 574
Otitis media in children, comparison of amoxicillin with alternative agents for the treatment of acute, 124S
Otitis media trials, microbiologic surrogate end points in clinical trials of infectious diseases: example of acute, 109S
Otitis media, predictive value of double tympanocentesis in acute, 105S
Overactive bladder and related comorbidities, costs associated with the management of, 511
Overdose of multiple chemotherapeutic agents, long-term clinical outcome after accidental, 1011

- P -

Pain, ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic, 1084
Pancreatitis, acute, associated with different combination therapies in patients infected with human immunodeficiency virus, 1044
Pancreatitis, propofol-associated hypertriglyceridemia and, in the intensive care unit: an analysis of frequency and risk factors, 1348
Panic disorder, exacerbation of, with rifampin therapy in a patient receiving citalopram, 435
Papillomatosis, cidofovir for the treatment of recurrent respiratory, a review of the literature, 977
Parkinsonism, quetiapine use in a patient with chronic schizophrenia and severe, 1651
Paroxetine, sertraline, and citalopram, persistence, switching, and discontinuation rates among patients receiving, 660
Peak flow meters and their effect on peak expiratory flow, gender differences in the use of, 526
Pediatric pharmacotherapeutic education: current status and recommendations to fill the growing need, 1277
Pentamidine-associated second-degree heart block and

sinus bradycardia, early-onset, case report and review of the literature, 899
Permethrin-induced neck dystonia, probable topical, 448
Persistence, decreased, to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition, 1729
P-glycoprotein, calcineurin inhibitor–induced nephrotoxicity and renal expression of, 779
Pharmacist detection of peripheral arterial disease through the use of a handheld Doppler, 797
Pharmacist intervention, long-term impact of a community, on cholesterol levels in patients at high risk for cardiovascular events (SCRIP-PLUS), 110
Pharmacist-administered diabetes mellitus education and management services, effectiveness of, 1809
Pharmacist-managed hepatitis C virus clinic, patient education and treatment strategies implemented at a, 1230
Pharmacodynamics and the prediction of efficacy in short-course antibiotic therapy: pediatric studies to validate the model, 159S
Pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics, future in vitro and animal studies: development of, 146S
Pharmacotherapeutic education, pediatric, current status and recommendations to fill the growing need, 1277
Pneumococcal pneumonia, murine models of, and their applicability to the study of tissue-directed antimicrobials, 134S
Pneumonia, blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired, 59
Pneumonia, murine models of pneumococcal, and their applicability to the study of tissue-directed antimicrobials, 134S
Pneumonitis, venlafaxine-associated interstitial, 626
Policosanol, meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus, 171
Polycystic ovary syndrome, thiazolidinediones for treatment of, 244
Postmenopausal osteoporosis, treatment of, 574
Pregnancy, treatment of acute myeloid leukemia during the second and third trimesters of, 1134
Primary prevention of coronary heart disease, aspirin under fire: aspirin use in the, 847
Propofol, lorazepam, and midazolam, for continuous sedation in critically ill patients, pharmacoeconomic modeling of, 1319
Propofol: an immunomodulating agent, 28S
Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors, 1348
Prostaglandins, relationships between the concentrations of, and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen, 18
Prostaglandins, retrospective evaluation of inhaled, in patients with acute respiratory distress syndrome, 184
Protease inhibitors and nonnucleoside reverse transcriptase inhibitors, elevated plasma concentrations of, in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review, 1068
Prothrombin time, barriers to patient self-testing of, national survey of anticoagulation practitioners, 265
Protozoal, bacterial, rickettsial, and spirochetal, infectious diseases, tick-borne, in the United States: a comprehensive review, 191
Pseudomonas aeruginosa, nosocomial infections due to multidrug-resistant, epidemiology and treatment options, 1353
Pulmonary edema, hydrochlorothiazide-induced noncardiogenic, an underrecognized yet serious adverse drug reaction, 1258

- Q -

QTc-interval–prolonging or hemodynamic effects, absence of, of a single dose of bitter-orange extract in healthy subjects, 1719
QT-interval dispersion, effects of methadone on, 1523
Quetiapine use in a patient with chronic schizophrenia and severe parkinsonism, 1651

- R -

Reductase inhibitors (statins), effect of 3-hydroxy-3-methylglutaryl coenzyme A, on high-sensitivity C-reactive protein levels, 1365
Reductase inhibitors, cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme A, based on results of the STELLAR trial: clinical implications for therapeutic selection, 270
Renal disease formula to estimate renal function, problems with the use of the modified diet in, 1283
Renal failure, acute, after placement of tobramycin-impregnated bone cement in an infected total knee arthroplasty, 876
Renal failure, intravenous immunoglobulin–associated acute, case series and literature review, 886
Renal function, problems with the use of the modified diet in renal disease formula to estimate, 1283
Renal impairment compared with controls, peak antifactor Xa activity produced by dalteparin treatment in patients with, 817
Renal insufficiency, enoxaparin-associated retroperitoneal bleeding in two patients with, 769
Renal insufficiency, use of highly active antiretroviral therapy in patients with, 698
Renal transplant recipient, celecoxib-induced nephrotoxicity in a, 773
Renin-angiotensin system, can the, protect against stroke? A focus on angiotensin II receptor blockers, 531
Respiratory drugs delivered by nebulizer, impact of a criteria-based reimbursement policy on the use of, and health care services utilization in Nova Scotia, Canada, 1248
Respiratory tract infections, gemifloxacin for the

treatment of, in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety, 717
Reverse transcriptase inhibitors, elevated plasma concentrations of protease inhibitors and non-nucleoside, in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review, 1068
Rhabdomyolysis, epinephrine overdose–associated hypokalemia and, in a newborn, 1266
Rickettsial, spirochetal, bacterial,and protozoal infectious diseases, tick-borne, in the United States: a comprehensive review, 191
Rifampin therapy in a patient receiving citalopram, exacerbation of panic disorder with, 435
Risperidone, interpreting serum concentrations, 299
Rituximab therapy in a patient with lymphoma, delayed-onset grade 4 neutropenia associated with, case report and literature review, 1151
Rosiglitazone-metformin versus glimepiride-metformin combination therapy, antithrombotic effects of, in patients with type 2 diabetes mellitus and metabolic syndrome, 637
Rosuvastatin for the treatment of hypercholesterolemia, 990

- S -

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus, 810
Sedation guidelines: has the road map brought us to the destination?, 1S
Sedation, daily interruption of continuous, 3S
Sedation, pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous, in critically ill patients, 1319
Sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit, adverse events associated with, 8S
Selective serotonin reuptake inhibitors, the use of tricyclic antidepressants and, in women who are breastfeeding, 411
Sertraline, paroxetine, and citalopram, persistence, switching, and discontinuation rates among patients receiving, 660
Severe sepsis treated with drotrecogin alfa (activated), predictors of hospital mortality for patients with, 26
Sevoflurane, inhalation anesthesiology and volatile liquid anesthetics: focus on isoflurane, desflurane, and, 1773
Sirolimus pharmacokinetics, effects of calcineurin inhibitors on, during staggered administration in renal transplant recipients, 646
Sleep in the intensive care unit, 34S
Smoking cessation, increase in international normalized ratio after, in a patient receiving warfarin, 1656
Smoking-cessation clinic, outcomes from an outpatient, 279
Society of Infectious Diseases Pharmacists, gram-positive resistance: pathogens, implications, and treatment options, insights from the, 1001
Society of Infectious Diseases Pharmacists, current issues in the development of a vaccine to prevent human immunodeficiency virus, insights from the, 741
Society of Infectious Diseases Pharmacists, expert clinical decision support systems to enhance antimicrobial stewardship programs: insights from the, 1116
Sodium bicarbonate, reversal of citalopram-induced junctional bradycardia with intravenous, 119
Sodium valproate, valproate modified-release granules, bioequivalence of a new sustained-release formulation of, compared with existing sustained-release formulations after once- or twice-daily administration, 35
Spinal cord injury, immunoactivation and altered intercellular communication mediate the pathophysiology of, 145
Spirochetal, bacterial, rickettsial, and protozoal infectious diseases, tick-borne, in the United States: a comprehensive review, 191
Staphylococcus aureus, community-associated methicillin-resistant: a review, 74
Staphylococcus aureus, trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant, 253
Statin therapy, cardiovascular morbidity associated with nonadherence to, 1035
Statins and osteoporosis: a clinical review, 228
Statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization, low myopathy rates associated with, 345
Statins, cost-efficacy analysis of, based on results of the STELLAR trial: clinical implications for therapeutic selection, 270
Statins, effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, on high-sensitivity C-reactive protein levels, 1365
Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus, 10
Steroid concentrations, effect of ginkgo biloba extract on plasma, in healthy volunteers: a pilot study, 1337
Steroid injection, central serous chorioretinopathy after epidural, 1141
Sterols and stanols, plant, versus policosanol, meta-analysis of natural therapies for hyperlipidemia, 171
Stimulants, assessment of adherence measures with different, among children and adolescents, 909
Streptococcus pneumoniae, pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against, with the use of Monte Carlo simulation, 1161
Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention, 1193

Stroke, and atrial fibrillation after cardiothoracic surgery, impact of prophylactic amiodarone on length of hospital stay, 320
Stroke, tactics for vascular protection after acute ischemic, 387
Sulfonylurea therapy, secondary failure rates associated with metformin and, for type 2 diabetes mellitus, 810
Surrogate end points, microbiologic, in clinical trials of infectious diseases: example of acute otitis media trials, 109S

- T -

Tegaserod, ischemic colitis, irritable bowel syndrome, and, an alternative viewpoint, 1684
Tegaserod-associated ischemic colitis, 620
Telithromycin, effects of itraconazole or grapefruit juice on the pharmacokinetics of, 42
Therapeutic interchange—2004, American College of Clinical Pharmacy Position Statement: guidelines for, 1666
Thiazolidinedione therapy, risk of hospitalization for heart failure associated with, a Medicaid claims–based case-control study, 1329
Thiazolidinediones for treatment of polycystic ovary syndrome, 244
Thrombocytopenia associated with intravenous ciprofloxacin, 1030
Thrombocytopenia, early-onset heparin-induced, after a 165-day heparin-free interval: case report and review of the literature, 615
Tick-borne bacterial, rickettsial, spirochetal, and protozoal infectious diseases in the United States: a comprehensive review, 191
Tiotropium, absence of electrocardiographic findings and improved function with once-daily, in patients with chronic obstructive pulmonary disease, 1708
Tissue-based antibiotics, future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for, 146S
Tissue-directed antimicrobials, murine models of pneumococcal pneumonia and their applicability to the study of, 134S
Tobramycin-impregnated bone cement in an infected total knee arthroplasty, acute renal failure after placement of, 876
Torsade de pointes, effects of buprenorphine on cardiac repolarization in a patient with methadone-related, 611
Toxic epidermal necrolysis, probable vancomycin-associated, 308
Tricyclic antidepressants and selective serotonin reuptake inhibitors, the use of, in women who are breastfeeding, 411
Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus, 253
Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia, 1820
Tumor necrosis factor-alpha and involuntary weight loss in elderly, community-dwelling adults, 313
Tumor necrosis factor-alpha antagonists, infections associated with, 1181
Tympanocentesis, predictive value of double, in acute otitis media, 105S

- V -

Vaccine, current issues in the development of a, to prevent human immunodeficiency virus, insights from the Society of Infectious Diseases Pharmacists, 741
Vancomycin-associated toxic epidermal necrolysis, probable, 308
Vascular protection, tactics for, after acute ischemic stroke, 387
Venlafaxine-associated interstitial pneumonitis, 626
Vitamin C, effect of high-dose, on hepatic cytochrome P450 3A4 activity, 1725
Vitamin C, effect of high-dose, on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers, 165
Vitamin K, low-dose, to augment anticoagulation control, 1746
Voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis, cost advantage of, 839
Voriconazole, intravenous, therapy in a preterm infant, 893

- W -

Warfarin adverse events requiring patient hospitalization, reduction in, after implementation of a pharmacist-managed anticoagulation service, 685
Warfarin and levofloxacin, retrospective evaluation of a possible interaction between, 67
Warfarin and moxifloxacin: additional evidence for a clinically relevant interaction, 904
Warfarin-azithromycin interaction: are we fishing with a red herring?, 630
Warfarin dosage, increasing reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy, 442
Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy, 1055
Warfarin therapy in an outpatient anticoagulation clinic, predictors of noncompliance with, 1801
Warfarin use in patients with atrial fibrillation, effect of access to anticoagulation management services on, 1062
Warfarin, enhanced antithrombotic effect of, associated with low-dose alcohol consumption, 303
Warfarin, increase in international normalized ratio after smoking cessation in a patient receiving, 1656
Warfarin, use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to, 157
Weight loss in elderly, community-dwelling adults, tumor necrosis factor-alpha and involuntary, 313
Weight-loss supplement, electrocardiographic effects of an ephedra-free, multicomponent, in healthy

volunteers, 654
Wound healing, effects of perioperative antiinflammatory and immunomodulating therapy on surgical, 1566
Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain, 1084
Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review, 1660
Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome, 1156